Hair Growth Is Induced by Blockade of Macrophage-derived Oncostatin M and Downstream Jak-stat5 Signaling in Hair Follicle Stem Cells by Wang, Etienne Cho Ee
HAIR GROWTH IS INDUCED BY BLOCKADE OF 
MACROPHAGE-DERIVED ONCOSTATIN M AND 
DOWNSTREAM JAK-STAT5 SIGNALING IN 
HAIR FOLLICLE STEM CELLS 
ETIENNE C.E. WANG 
Submitted in Partial Fulfillment of the  
Requirement for the Degree of  
Doctor of Philosophy
under the Executive Committee  







HAIR GROWTH IS INDUCED BY BLOCKADE OF MACROPHAGE-DERIVED ONCOSTATIN M 
AND DOWNSTREAM JAK-STAT5 SIGNALING IN HAIR FOLLICLE STEM CELLS  
ETIENNE C.E. WANG
Our lab recently described a role for JAK-STAT signaling in the maintenance of quiescence 
during the murine hair cycle. Research into signaling pathways and cytokines/growth factors 
involved in the mammalian hair cycle has not focused extensively on the JAK-STAT pathway. In 
this thesis, I investigated the upstream effector(s) and downstream mechanisms of JAK-STAT 
signaling in the HFSC during telogen, using a variety of methods, including murine conditional 
mutants of the JAK-STAT pathway, pharmacological and immunological techniques. The 
mechanism through which OSM exerts this effect is via JAK-STAT5 signaling downstream of 
the OSM receptor, which is antagonized by pharmacological JAK inhibition. Conditional 
epidermal ablation of OSMR or STAT5 during early- and mid-telogen (P42 – P60) shortens the 
telogen phase significantly, and inhibition of macrophages by way of neutralizing antibodies, 
small molecule inhibitors, and genetic ablation (with Csf1r-CreER::R26-iDTR mice) during 
telogen also promotes hair growth. Single-cell RNA sequencing of dermal immune cells across 
murine telogen identified a distinct subset of TREM2+ macrophages that are enriched for OSM, 
and gene-set analysis suggests these “trichophages” are similar to the microglia of the central 
nervous system. I show that this distinct subset of TREM2+ macrophages predominate during 
early- and mid-telogen, where they produce Oncostatin M (OSM), which is sufficient to maintain 
quiescence of hair follicle stem cells (HFSCs). Proliferation of HFSCs and hair growth is 
associated with depletion of this subset of TREM2+ macrophages. Interestingly, macrophage 
markers and OSM were found to be upregulated in the balding scalp of males with androgenetic 
alopecia, suggesting that this mechanism is physiologically relevant in the control of human hair 
cycling. 
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CHAPTER 1. INTRODUCTION 
 
The hair follicle (HF) is a complex appendage, exclusive to mammalian skin, that serves 
thermoregulatory, camouflage and aesthetic functions. The HF as an organ provides 
tremendous insights into how stem cells interact with their niche, and with the surrounding cells 
of their dermal macroenvironment (eg. adipocytes). Semi-autonomous, periodic molecular 
signals within the HF results in a phenomenon known as hair cycling in mammals, which allows 
for timed shedding and regeneration of hair and fur. These signals are influenced by 
environmental and systemic cues that may accelerate or inhibit this cycle.  
 
The concept of growth Inhibitory factors in tissues was first put forward by Claude Bernard in 
1878 [1]. These factors were given the name “chalones” from the Greek chalao that means “to 
lower” or “to reduce in strength” around 1913, and they have been hypothesized to mediate 
tissue homeostasis by preventing proliferation and hyperplasia [2]. Their existence in various 
tissues, in particular the bone marrow and skin, have been illustrated by classic experiments 
whereby filtrated tissue extracts were able to prevent mitosis of similar cell types in vitro [3, 4]. 
In the skin, chalones have been proposed inhibit hair growth, and dermal extracts during the 
“rest phase” of the hair cycle was able to inhibit hair growth when injected into another mouse 
[5]. In this thesis, I explore whether chalones can maintain HF stem cell quiescence via the JAK-







1.1. The mammalian hair cycle 
 
The mammalian hair cycle is a tightly coordinated process whereby the hair follicle undergoes 
distinct phases of growth (anagen), regression (catagen) and rest (telogen) [6-8]. Each phase of 
the hair cycle requires complex cellular interactions and molecular signals that direct the hair 
follicle stem cells (HFSCs), their epithelial progeny in the outer and inner root sheaths 
(ORS/IRS) of the HF, and the instructional mesenchyme (the dermal papilla, DP) to either 
produce or shed a hair shaft [7, 9].  
 
1.1.1. The murine hair cycle 
 
The hair cycle in the mouse begins at the end of HF morphogenesis (Figure 1.1), which starts 
with complex epithelial-mesenchymal crosstalk during embryogenesis (E14.5) that creates the 
epidermal placode that develops into a hair follicle, and lasts until about post-natal day 19 (P19). 
During morphogenesis, the establishment of the various epidermal and HF stem cell 
compartments, along with their niches are achieved by a complex combination of Dysplasin A 
(EDA), Wnt, Bone Morphogenetic Protein (BMP), Fibroblast Growth Factor (FGF) and Sonic 
Hedgehog (Shh) signaling. Genetic disruption of any of these signaling pathways have profound 
consequences on HF structure and function [10-14], and many of these pathways have been 
also shown to be involved in the subsequent phases of adult HF cycling [9]. The DP, which 
develops via specialized dermal fibroblast condensates during morphogenesis, is comprised of 
mesenchymal cells that secrete many of the signals that control the activation, proliferation, and 
differentiation of the HFSCs throughout the life of the mouse [15]. The first two hair cycles in the 
mouse are tightly coordinated and synchronized across the dorsal skin, whereas they are 
largely asynchronous in adult humans and guinea pigs [16, 17]. The highly stereotypical 
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orchestration and synchronization of the hair cycle has been well documented in C57BL/6 mice 






Figure 1.1. Hair Follicle 
Morphogenesis progressing 
into the adult hair cycle in 
C57BL/6 mice. Adapted from 
Stenn et al, 2001. Epithelial-
mesenchymal interactions 
between the epidermal placode 
and embryonic mesenchyme 
leads to downgrowth and 
invagination of epithelial 
precursors. Complex patterning 
and morphogen interactions 
lead to the establishment of 
stem cell compartments that 
persist through adulthood. At 
around P16-P19, 
morphogenesis is complete and 
the newly formed HF undergoes 
the first catagen (P19-P22), 
followed by a short first telogen 
(P22-P28), before entry into the 
first anagen phase (P28-P42). 
This proceeds synchronously 
over the entire dorsal skin of the 
mouse for the first 2 cycles, after 
which it becomes patchy and 
unpredictable. Many of the 
signaling pathways utilized 
during morphogenesis are 
reprised during the hair cycle. 
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Anagen induction, whereby “resting” telogen follicles enter the next growth phase, may occur 
spontaneously during the normal hair cycle, or can be induced by depilation, plucking or full-
thickness wounding of the mouse telogen skin [18]. Depilation- and plucking-induced anagen 
synchronizes the hair cycle in murine skin, and are useful techniques for studying anagen 
progression in the mouse. Several lines of evidence point to differential regulation of 
spontaneous versus experimentally-induced anagen, and suggest these processes are 
mechanistically distinct (see section 1.4.3) [19].  
 
1.1.2. The human hair cycle 
 
Human HF morphogenesis occurs entirely during gestation, with epithelial-mesenchymal 
signaling producing the initial lanugo hairs that cover the body surface of the fetus. The human 
hair cycle is believed to have a very transient synchronized phase at birth, which may serve to 
shed the lanugo hairs of the newborn [20]. These hairs are replaced first with vellus hairs, and 
then with terminal HFs, particularly on the scalp, around the time of birth. Unlike mouse dorsal 
hair, which spends a large proportion of the hair cycle in telogen, the conspicuous terminal 
human hairs on the scalp are mostly in the anagen phase. In fact, human scalp hairs may spend 
up to 7 years in anagen, which accounts for the length that human hair may achieve [21]. 
Catagen and telogen lasts about 1-2 weeks and 3 months in humans, respectively. As such, 
studying human hair cycling is very difficult, and computational models [22] or mouse xenograft 
models [23] have been developed to address this. 
 
Understanding the controls of hair cycling can help clinicians and researchers address disorders 
associated with arrested or prolonged telogen, which presents clinically as thinning or shedding 
hair. Telogen effluvium (TE) is characterized by an inverted anagen:telogen ratio, typically after 
5 
 
physical or emotional stress that diverts resources from the hair cycle [24]. TE is common post-
partum, or post-surgery, during which alarming amounts of hair is shed 4-6 months after the 
precipitating event. In androgenetic alopecia (AGA) [25], miniaturized HFs in androgen-sensitive 
areas of the scalp are unable to enter the anagen phase. At the moment, the distinction 
between a miniaturized HF of AGA and the vellus hairs of human telogen are purely clinical [26], 
and their molecular and cellular pathologies are unknown. Although our knowledge of the 
molecular controls of human hair cycling is limited, we may use mouse models to delineate 
basic concepts of hair biology that may be extrapolated to humans. 
 
1.2. Molecular mechanisms of hair cycle control 
 
This section describes the molecular signals and mechanisms involved in the control of the 
murine hair cycle, which has been described in detail by Muller-Rover et al in the C57BL/6 




After HF morphogenesis in the mouse is compete (around P16-19), the fully formed HF 
undergoes its first catagen phase (Figure 1.1), whereby proliferation of the keratinocytes in the 
ORS and matrix ceases, and the melanocytes and epithelial cells of the HF matrix undergo 
apoptosis. This process of controlled organ deletion results in the retraction of the non-
permanent portion of the HF (ie. the epidermal tissue below the bulge) and the migration of the 
DP from the deep dermis to a more superficial position nearer the HFSC bulge, separated by 
the secondary hair germ (HG). The regression of keratinocytes during catagen is an active 
process, and requires signaling by molecules like FGF-5, parathyroid hormone-related protein 
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(PTHrp) and IGF-1, amongst others. Genetic disruption of these signaling pathways in mice 
results in prolonged anagen, failure to enter catagen, and elongated hair shafts [27-31]. In the 
mouse, FGF-5 mutations are associated with the Angora phenotype, whereby the prolonged 
anagen phase of the dorsal coat provides these mice with longer, scruffier fur [32]. In humans, 
mutations in the FGF-5 gene is associated with trichomegaly, whereby a prolonged anagen 
phase is characterized by longer, thicker eyelashes in affected individuals [33]. 
 
The removal of cellular debris of catagen is likely carried out by macrophages [34], which have 
been observed to cluster around catagen follicles, and have been postulated to be the source of 
FGF-5 [27]. Recent advances in intravital imaging using two-photon confocal microscopy has 
also implicated the epithelial cells themselves to be able to clear neighboring apoptotic cells by 
phagocytosis during catagen [35]. As the HF regresses, it leaves behind a “fibrous tract” of 
extracellular matrix and macrophages [34, 36], which can be observed on histological sections 




When the DP has migrated up to its position near the bulge following catagen, the “resting” 
phase of the hair cycle, known as telogen, begins. Telogen is characterized by its lack of 
proliferation, and has historically been described as a quiescent period of the hair cycle. 
However, this concept has been challenged in recent years by several groups, who propose 
that the lack of proliferation does not signify a lack of activity [37]. Indeed, the telogen phase has 
been shown to be rich in inhibitory signals that maintain the quiescence of HFSCs. Paus et al 
showed that murine telogen skin contains a factor that could inhibit anagen when extracted and 
injected into another mouse [5], raising the possibility for the presence of a naturally-occurring 
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“chalone” or a growth-inhibitory factor [2] of HFSCs. The first telogen phase in a C57BL/6 
mouse is short, and lasts about a week from P19 to P28. The second telogen is much longer, 
and can last from P45 to around P80-P100, making the second telogen more amenable to 
studying the molecular drivers of telogen.  
 
Immediately after catagen, the skin is in a state known as “refractory telogen”, when anagen 
does not occur spontaneously, and cannot be induced by plucking or depilation. Refractory 
telogen is associated with high BMP activity, which is a potent inhibitor of HFSC activity [38] 
(Figure 1.2). BMP levels in the dermis begin to decline during mid-telogen, at which time the 
skin progresses to “competent telogen”, wherein the HFs become receptive to 
macroenvironmental signals that initiate the next phase of anagen [39]. Using whole-mount in 
situ hybridizations, Plikus et al showed Bmp2 and Bmp4 mRNA to have a periodic expression 
pattern in relation to the hair cycle: being prominently expressed in late anagen/refractory 
telogen, and absent in competent telogen. 
 
Figure 1.2. Interactions of signaling networks during the hair cycle. Adapted from Plikus et al, 2008. 
Activating signals (Wnt/β-catenin) and inhibitory signals (BMP) are expressed in an overlapping manner 
to determine the potential of the skin for anagen induction. “Refractory telogen” immediately following 
catagen is characterized by high BMP activity, which prevents HFSC activation. As BMP declines, 
“competent telogen” is achieved, allowing the next wave of anagen to propagate through. 
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Other inhibitory signals are derived from within the HF itself. The K6+ inner bulge was found to 
produce FGF-18 and BMP6 to maintain quiescence of the outer bulge cells [40]. Intriguingly, the 
K6+ inner bulge cells were found to be derived from cycling cells in the ORS from the previous 
hair cycle, and during telogen they provide signals to form the quiescent niche for bulge HFSCs. 
Hsu et al showed that ablating these cells during telogen with a Sox9-iDTR genetic model 
resulted in shedding of the telogen coat and precocious entry into the next anagen phase. 
During telogen, the HFSC of the bulge and HG are characterized by pSMAD1/5 signaling 
(downstream of intrafollicular and dermal BMP signals), as well as Axin2 signaling (likely 
autocrine Wnt signaling that is essential for stem cell self-renewal) [41]. 
 
In addition to Axin2, other molecules have been identified as markers of HF stem cell identity in 
the bulge and HG during telogen (Figure 1.3). CD34, which is expressed on other stem cells, 
immune cells and vascular structures, is restricted to the bulge HFSC in the epidermis, and is a 
reliable cell-surface antigen for fluorescence-activated cell sorting (FACS) of mouse HFSCs 
[42]. Isolation of bulge HFSCs during various stages of the hair cycle have identified Wnt and 
BMP signaling to be important in maintaining bulge identity [43]. The Lim-homeodomain 
transcription factor (Lhx2) is expressed by both the bulge and HG HFSCs, and is co-expressed 
with other stem cell markers SOX9, Tcf4 and Lgr5 [44]. In the bulge, Lhx2 functions upstream of 
SOX9 and Tcf4 to promote the wound healing capacity of the bulge HFSC, while it suppresses 
proliferation and maintains quiescence of the HG. In both the bulge and HG, Lhx2 also 
maintains cell polarity and stem cell identity within its niche [45]. NFATc1, which acts 
downstream of BMP and calcineurin signaling, is also a quiescence factor for the HFSC [46]. 
FoxC1, which may regulate both BMP and NFATc1 [47], has also been described as a 




While BMPs and FGF-5 exert inhibitory effects on HFs during catagen and telogen, it can be 
argued that they may not function as true chalones in this system. Criteria for chalones, as 
defined by Houck in 1973 [2], are 1) Total cell specificity; 2) Lack of species specificity; and 3) 
Reversibility. BMP signaling has may other roles in HF morphogenesis and cycling. BMP 
signaling is required for patterning of the HF matrix during anagen [49] and for differentiation of 
the layers of the IRS [13], and is also required for the inductive properties of the DP [50]. FGF-5, 
while promoting catagen, is also required for maintenance of HF structure, as Angora mice are 
described to have dystrophic hair canals with secondary hyperplasia [32]. A true chalone would 




Figure 1.3. Factors governing quiescence of HFSCs during telogen. BMP signaling predominates from the inner 
bulge, macroenviroment and the DP. The HFSC compartment (bulge and HG) express stem cell markers that are 





At the end of telogen, the decline of inhibitory signals (BMPs), coupled with increase in 
activating signals from the DP, result in activation of the HFSC, making the start of spontaneous 
anagen. DP-derived Wnt signaling results in stabilization of β-catenin in the adjacent secondary 
HG [51], leading to proliferation which is first observed in this compartment [52]. In addition to 
proliferating and differentiating into the ORS, the HG cells also begin to secrete Shh, which in 
turn activates the bulge HFSCs, which are positioned just above the HG [53]. As the HG 
proliferates and differentiates into the ORS, it is replenished by less frequent divisions from the 
bulge. As anagen progresses, and the DP migrates further and further away from the bulge 
toward the deep dermis, proliferation in the bulge becomes less frequent. Regeneration of the 
HF is occurs mainly by the proliferative activity of the epithelial cells of the ORS and matrix, 
which further differentiate to give rise to the concentric layers of the IRS and the hair shaft. 
 
The DP is essential for the initiation of anagen [54]. Precise laser ablation of the DP prevents 
the HF from entering anagen [55], whereas ablation of HFSC in the bulge or HG does not. It 
appears that neighboring HFSCs are able to differentiate to fill the space in the niche left by 
laser ablation of bulge or HG cells [56]. As anagen progresses, the telogen DP enlarges from a 
small cluster of cells to a large anagen DP that is comprised of up to 3000 cells depending on 
the hair type. Large anagen vibrissa hairs of the whiskers harbor 3000 cells, while various 
pelage hairs on the dorsal coat vary in DP sizes. [57]. The cells of the DP are replenished by 
stem cells found in the dermal cup, which also supplies progeny to the dermal sheath [58, 59]. 
By the end of anagen, the DP is deep in the subcutaneous adipose tissue, and the fully-
developed terminal anagen HF extends through all the layers of the skin. The dermal and 
subcutaneous adipocytes also proliferate and expand throughout anagen, and contribute to 
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overall skin thickening during this phase of the hair cycle [60, 61]. Additionally, dermal 
adipocytes secrete PDGFα that regulates HFSC activity [62], and subcutaneous adipocytes are 




1.3. Other cell types during the hair cycle 
 
The subcutaneous adipocytes are not the only cell type that interacts with the cycling HF. Other 





Melanocytes in mammals are found in the basement membrane of the epidermis, and the matrix 
of the anagen HF, where they produce melanin pigments that are transferred to keratinocytes in 
melanosomes. In C57BL/6 mice, the epidermis is devoid of melanocytes, which accounts for the 
pink appearance of telogen skin. Melanocyte stem cells in the bulge are activated by stem cell 
factor (SCF) secreted by the activated Krox20+ hair matrix [64], which signals via c-kit to initiate 
proliferation and migration of melanocytes into the HF matrix [65]. This process is very tightly 
coordinated with the hair cycle, and the darkening of telogen skin due to increased 
melanogenesis reliably heralds the onset of anagen. 
 




Guard hairs, the largest HFs of the mouse pelage which comprise about 1% of the coat hairs, 
are associated with Merkel cell complexes that mediate sensation derived from pressure and 
mechanical stimuli [66]. The Merkel cell complex is made up of a touch dome containing 20-50 
Merkel cells, and somatosensory afferent innervation. Epidermal innervation and Merkel cell 
numbers have been described to fluctuate during the hair cycle [67-69], and recently, Marshall 
et al showed that Merkel cell numbers decrease during anagen, increase before catagen, and 
maintain their numbers throughout telogen [70]. While the signaling pathways that influence 
these processes have yet to be described, it is likely that the developmental signaling pathways 
of the hair cycle (ie. Wnt, BMP, FGF, Shh) may also play a role in neuronal and Merkel cell 
maintenance and remodeling of touch domes.  
 
1.3.3. The immune system and the hair cycle 
 
The role of the immune system in the maintenance of the stem cell niche has been described in 
many systems. Besides their given role in the maintenance of the hematological niche in the 
bone marrow [71], immune cells are widely implicated in processes like embryogenesis [72], 
post-natal homeostasis and development [73], and regeneration [74].  
 
Paus et al have described the distribution and fluctuations of immune cells associated with the 
murine adult hair cycle [75]. Langerhans cells and γδ T cells were restricted mainly to the 
epidermis, where they carry out immunosurveillance. CD4+ and CD8+ T cells were rare in 
healthy skin and HFs. MHC Class II+ cells, which include macrophages, monocytes and 
dendritic cells (DCs), were abundant in mouse skin and were found in close proximity to HFs 
[36], especially during late anagen.  Macrophages have been implicated in the clearance of 




Mast cells have also been described to be closely associated with murine HFs. Using 
immunohistochemistry studies, Maurer et al showed that mast cell numbers peaked in late 
anagen, and degranulated just before spontaneous catagen [76]. The authors proposed that 
mast cell products like substance P (SP) and adrenocorticotrophic hormone (ACTH) mediate HF 
involution during murine catagen [77]. SP and other neurotransmitters like brain-derived 
neurotrophic factor (BDNF) have been implicated in precipitating catagen, and may be linked to 
HF-associated autonomic innervation [78, 79], which in turn may influence mast cell 
degranulation. 
 
1.3.4. Immune cells and the telogen-to-anagen transition 
 
The telogen-to-anagen transition reflects the activation of quiescent HFSCs to initiate 
proliferation and differentiation of ORS and IRS that results in formation and elongation of the 
hair shaft. The onset of hair growth can be observed readily in the mouse. 
 
The transition from telogen to anagen may occur spontaneously, during the normal unperturbed 
murine hair cycle, or it can be induced (Figure 1.4, Table 1.2). In the mouse, depilation (with 
depilatory creams) and plucking (active physical extraction of HFs) during telogen can stimulate 
the growth of the next hair cycle [80], and is frequently utilized to study the anagen phase in a 
coordinated and synchronized manner [81]. Plucking of telogen HFs is believed to stimulate 
CCL2 secretion by the damaged HFs, which recruits macrophages to the vicinity where they 
release TNF to initiate anagen [82]. This process is dependent on the phase of telogen 




Ali et al recently demonstrated that depilation-induced anagen may be mediated by FoxP3+ T 
regulatory cells via the Jagged1/Notch signaling pathway [83]. Genetic ablation of T regs with a 
FoxP3-iDTR mouse model showed inhibition of depilation-induced anagen, which could be 
replicated in FoxP3-Cre::Jag1FL/FL mice. 
 
During wound healing in rodents, it has been shown that larger wounds regenerate with de novo 
HFs arising from the healed scar tissue by a process called wound-induced HF neogenesis 
(WIHN) [84]. This process recapitulates HF morphogenesis, and has been shown to depend on 
FGF-9 produced by γδ T cells [85], which are recruited by factors released by damaged 























































































































































































































































1.3.5. Macrophages and the hair cycle 
While the role of dermal macrophages during wound healing and psoriatic inflammation have 
been established [87, 88], their function in non-homeostatic or inflammatory processes in the 
skin have not been well studied. Their proposed functions during the hair cycle have been 
inferred from their anatomical associations with HFs, and evidence of their actual function has 
only recently been uncovered. 
Macrophages have been implicated in the control of the telogen-to-anagen transition. 
Castellana et al showed that macrophage numbers peak during mid-telogen, and declined 
during late telogen, at which point they underwent apoptosis to release Wnt signals that induced 
HFSC activation in telogen HFs [89]. The authors also show that macrophage depletion during 
telogen using clodronate liposomes resulted in anagen initiation. 
Several non-immune roles macrophages in various tissues have also been described. In the 
heart, macrophages have been shown to facilitate electrical conduction [90] In the brain, the 
microglia (which are innate immune cells with the same ontogeny as macrophages) have 
essential housekeeping and regulatory functions that maintain synaptic function and neuronal 
connects. Microglial dysfunction has been associated with neurodegenerative disease like 
Alzheimer’s disease [91]. In the skin, microglia-like cells (expressing the marker Aif-1/Iba-1) 
have been described to be associated with Merkel cell-neurite complexes, where they have 
been postulated to participate in remodeling and regeneration of neuronal structures (D. Owens, 
personal communication). This suggests that dermal macrophages may play a more significant 
role in tissue homeostasis of the skin and HF than previously appreciated. 
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1.3.6. Tissue resident macrophages 
Dermal tissue-resident macrophages (TRMs) are likely to be heterogenous [92], and are 
probably mostly unpolarized. The “M1” and “M2” subsets that were described and loosely 
analogous to Th1/Th2 reactions are unlikely to predominate at steady-state [93]. While M1 
“inflammatory” macrophages are believed to be important in dealing with bacterial and viral 
infections, M2 macrophages are associated with tissue repair and resolution of the inflammatory 
state [94]. M2 markers like CD163 and CD206 (MRC1) have been used to identify M2-like “anti-
inflammatory” macrophages, while MHC Class II expression and production of cytokines like 
Interferon-γ (IFN-γ), IL-1b and TNF have been used as putative “M1-like” markers. Other than 
their scavenging function, M2 TRMs may play an anti-inflammatory role by producing IL-4 and 
IL-10 [95]. Unpolarized TRMs may represent the “M0” subset, characterized by pan-
macrophage markers CD68 and Csf1r. Dermal TRMs are dependent on the growth factor Csf1 
(signaling via its receptor Csf1r) for maturation [96], and a null mutation in either Csf1 or Csf1r is 
associated with  dramatic loss of dermal TRMs [97]. 
Unlike the microglia of the central nervous system (CNS) and the Langerhans cells of the 
epidermis, the dermal macrophages are constantly being replenished by circulating monocytes. 
Early tissue-resident macrophages like the microglia are seeded during embryogenesis from 
progenitors in the yolk sac around E8.5, and replenish themselves throughout the adult life [98]. 
Adult dermal macrophages, on the other hand, are almost entirely made up from circulating 
monocyte precursors, and only have a minimal contribution from the yolk sac [99]. This may 
reflect the function of the skin as a barrier organ, requiring a constant flux of immune cell 
participants, or it may also be related to hair cycling itself, which represents a controlled 
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regenerative cycle that may require constant macrophage support for the turnover of epidermal 
cells. 
 
1.4. JAK-STAT signaling and the hair cycle 
 
1.4.1 Effects of JAK inhibitors on the hair cycle 
 
Our previous genetic studies in Alopecia Areata (AA) identified NKG2D+ CD8+ T cells to be the 
main pathogenic effectors for the disease [100-103]. This led to the interrogation of JAK 
inhibitors as a novel treatment modality for AA, targeting the JAK-STAT pathways that provide 
survival signals to the NKG2D+ CD8+ T cells downstream of IL-15 and IFNγ. Intriguingly, in the 
course of investigating the effects of JAK inhibitors on murine AA, it was observed that topical 
application resulted in thicker, more robust hair regrowth compared with systemic delivery. This 
effect was replicated in non-AA C57BL/6 mouse telogen skin [104] where topical JAK inhibitors 
were found to rapidly induce hair growth, in a manner analogous to physiological, spontaneous 
anagen. Further, using a qRT-PCR array of mouse dorsal skin throughout the hair cycle, JAK-
STAT3 and JAK-STAT5 signaling were the most dynamically expressed, and their activity 
unexpectedly peaked during telogen. This invited us to postulate whether JAK-STAT signaling is 
necessary for maintaining of quiescence of HFSCs during telogen.  
 
1.4.2 The JAK-STAT pathway 
 
The JAK-STAT pathway is one of the most ubiquitous and pleiotropic signaling pathways in 
eukaryotic cells, and is a common downstream effector for many growth factors and cytokines. 
It was discovered in the late 1980s as a pathway downstream of interferon signaling, and many 
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of its components were cloned, characterized and named by the mid-1990s [105]. In mammals, 
the pathway is comprised of four JAKs (JAK1, JAK2, JAK3, Tyk2), and seven STATs (STAT1, 
STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Ligand binding to cell surface receptors 
results in a conformational change in the cytoplasmic domain of the receptors, which in turn 
activates the specific JAK molecules that are associated with the receptor. This leads to trans-
phosphorylation of the JAKs, exposure of Src-homology (SH2) domains that recruit specific 
STAT protein dimers to the receptor complex. The STAT dimers are in turn phosphorylated by 
the JAKs, which allows for their translocation into the nucleus where they act as transcriptional 
regulators in various cellular processes. While JAK/STAT interactions are quite promiscuous (ie. 
all JAKs are potentially able to phosphorylate all STATs), the cell surface receptor and co-
receptor structure and stoichiometry dictate the specific combinations of JAK and STAT 
molecules that are recruited during ligand binding in the particular cell. This gives rise to a 
remarkable combinatorial diversity of JAK-STAT signaling that is highly cell-type- and context-
dependent [106]. 
 
Global constitutive knock-out experiments reveal JAK1, JAK2 and STAT3 to be the only 
embryonic-lethal components of the JAK-STAT pathway [107-109]. Genetic disruption of the 
other components results in varying degrees of hematological and immune deficiencies [110, 
111], but skin and hair morphogenesis appear to be normal. While Tyk2 and STAT3 mutations 
in humans are associated with innate immune defects, elevated serum IgE and atopic dermatitis 
[112-114], no distinct hair phenotype has been described in these patients.  
 




In order to circumvent the embryonic lethality of STAT3, Sano et al developed a K5-
Cre::STAT3FL/FL mouse model that restricted STAT3 knock-out to the basal K5+ stem cells of 
the epidermis from E14.5 (constitutive knock-out) [115]. These mice were viable and underwent 
normal skin and hair morphogenesis and development, such that epidermal thickness, hair 
length and thickness were unaffected up to P11. Interestingly, although HF morphogenesis was 
normal, mutant mice were unable to enter the first spontaneous anagen at around P28. These 
mice also had delayed wound healing, likely a result of impaired keratinocyte migration. 
Surprisingly, mutant mice were able to enter anagen after plucking, or after topical application of 
phorbol 12-myristate 13-acetate (PMA) [19]. As the K5-Cre::STAT3FL/FL mice aged, they 
developed alopecia, scales, crusts and spontaneous ulceration. These set of experiments 
suggest that while STAT3 is not necessary for skin and HF morphogenesis, it is required for 
subsequent processes that require keratinocyte motility such as spontaneous hair cycling, 
wound healing and possibly maintaining proper barrier function and integrity. K5-
Cre::STAT3FL/FL mice were also protected against epithelial carcinogenesis [116], which appears 
to be a STAT3-dependent process, and constitutively-active STAT3 mutants developed 
squamous cell carcinomas (SCC) at a higher rate [117]. These complementary studies conclude 
that JAK-STAT3 signaling in the HF is central to the activation and differentiation of HFSCs, in 
HF regeneration during the spontaneous hair cycle, wounding healing, and carcinogenesis. 
Since JAK-STAT3 signaling is associated with active processes like keratinocyte migration and 
differentiation, blocking this pathway with JAK inhibitors is not expected to promote hair growth 
during telogen. 
 




Global STAT5 knockout mice are growth-stunted with mammary gland development defects, 
infertile, and have severe immunodeficiencies, but appear to undergo normal HF 
morphogenesis [118, 119]. However, the effect of STAT5 deletion on the adult hair cycle in 
these mice were not investigated. 
 
HFSC quiescence in mice resulting from JAK-STAT5 signaling has been previously described in 
the context of pregnancy by Goldstein et al [120]. Systemic prolactin (PRL) secreted by the 
pituitary gland during pregnancy and lactation was shown to maintain HFSC quiescence in 
mice, possibly to divert resources to the developing fetuses. It is possible that the JAK-STAT5 
axis utilized to maintain HFSC quiescence has physiological functions outside pregnancy and 
lactation. 
 
Notably, JAK-STAT5 signaling also maintains the quiescence of stem cells in other systems. 
Conditional STAT5 knock-out in hematological stem cells (HSCs) using an Mx-
Cre::STAT5a/bFL/FL mouse model showed increased loss of quiescence, proliferation and 
subsequent apoptosis of the stem cell compartment [121]. Stem cells of the liver (hepatic 
stellate cells, HSCs) have also been shown to rely on JAK2-STAT5 signaling to maintain 
quiescence in response to vitamin A and insulin [122].  
 
In the HF, activated pSTAT5 is prominently expressed in the DP throughout the hair cycle, and 
may play a role in maintaining DP identity and its ability to initiate each round of anagen [123]. 
However, we have noticed that pSTAT5 expression in the DP tends to be constant, and does 
not fluctuate with the phases of the hair cycle [104]. Interestingly, in the HFSCs, pSTAT5 
expression is restricted transiently to early- and mid-telogen [104, 124], positioning it as a likely 




1.4.5 Potential effectors of JAK-STAT mediated quiescence in the HFSC 
 
The signaling pathways employed during HF morphogenesis have mainly been described as 
significant contributors to the adult the hair cycle. Inhibitory signals during telogen have been 
attributed to BMP-2 (from the subcutaneous adipocytes), BMP-4 (from within the hair follicle) 
[39], and BMP-6 and FGF-18 (from the K6+ inner bulge) [40]. However, none of these 
molecules signal through the JAK-STAT signaling pathway. As stated above, epidermal ablation 
of STAT3 had no adverse effect on HF morphogenesis, and STAT5-KO mice also seem to 
undergo normal HF development. This suggests that while JAK-STAT signaling was not 
essential for HF morphogenesis during embryogenesis, it has been utilized as one mechanism 
to coordinate the hair cycle in adulthood. 
 
Candidates for the upstream ligand that maintains JAK-STAT signaling in the HFSC are 
currently unknown. To narrow down the likely candidates, all growth factors and cytokines 
whose receptors signal through the JAK-STAT pathway were considered (Figure 1.4, Table 
1.1). Most cytokines that signal via the common γ-chain (eg. IL-2, IL-15) are involved in T cell 
development and differentiation [125], and were unlikely candidates for inhibitory effects on 
stem cells. Growth factors and hormones were also more likely to have activating functions, and 
most induce differentiation or migration in keratinocytes. This left the fascinating family of 
cytokines that includes IL-6, whose members have varied and sometimes inhibitory effects on 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.5. Oncostatin M and the IL-6 family of cytokines 
 
1.5.1. The IL-6 family of cytokines 
 
The IL-6 family of cytokines include IL-6, Oncostatin M (OSM), Leukemia Inhibitory Factor (LIF), 
IL-11, cardiotrophin-1 (CT-1) and ciliary neurotrophic factor (CNTF). The receptors for these 
cytokines require the co-receptor gp130 for signaling transduction via the JAK-STAT pathway, 
mostly via JAK1, JAK2 and Tyk2, and downstream STAT1, STAT3 and STAT5 [190]. 
Depending on the cell and tissue type, this family of cytokines are also able to signal via the 
PI3K-Akt and MAPK pathways. While IL-6 itself is able to induce gp130 homodimerization [191], 
all other members of the family signal through heterodimerization of their nascent receptor with 
gp130.  
 
IL-11 and CT-1 are mainly associated with active processes, such as airway inflammation [192] 
and cardiac muscle hypertrophy [193] respectively, and both have growth-promoting actions on 
neurons from dorsal root ganglia [194]. However, they have not been shown to have any 
inhibitory or quiescence-related functions (Table 1.1). Other members of the family have a more 
varied and pleiotropic range of functions. LIF signaling is essential for the survival and self-
renewal of embryonic stem cells (ESCs) in mice and humans [141, 195], and inhibits 
differentiation and proliferation in the COS-1 cell line via the JAK-STAT3 pathway [196]. Both 
LIF and CNTF also promote the survival of co-cultured rat Sertoli cells and gonocytes without 
affecting their proliferation [143]. 
 
IL-6 is an acute-phase cytokine that has pro-inflammatory roles in auto-inflammatory diseases 
like rheumatoid arthritis [197]. In the skin, IL-6 overexpression leads to reduced body weight, 
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sparse hairs, and increased epidermal keratinization without evidence of hyperproliferation 
[132]. Levels of IL-6 are increased significantly in lesional psoriatic skin, and IL-6 promotes 
keratinocyte proliferation in vitro [134]. However, Kwack et al showed that IL-6 inhibited HF 
matrix proliferation in human HF organ cultures, and could induce catagen when injected into 
the skin mice in anagen [131]. Paradoxically, IL-6 injected into the telogen skin Wistar rats was 
able to induce anagen [198], which may be due to species differences.  
 
1.5.2. Effects of OSM on the hair cycle 
 
In humans, OSM was first discovered as a negative growth regulator of the A375 melanoma cell 
line [136], at a time when much research was focused on identifying endogenous regulators of 
cancer cell growth. While OSM was first isolated in the supernatant of histiocytic lymphoma cells 
[136], it was found to be more reliably obtained from macrophage cell lines [199]. OSM was 
found to have pleiotropic properties, and (in humans) signals via the Leukemia Inhibitory Factor 
receptor (LIFRβ) in addition to OSMRβ. Its effects have been shown to be tissue- and context-
dependent, acting as a growth inhibitor in some cell lines, and as an activator in others [200, 
201]. These receptors were given the suffix -β because they were recruited second to the 
ligand-gp130 complex [202], unlike the α-receptors of IL-6R which were recruited first. 
 
Yu et al showed that OSM was able to inhibit human HF growth in organ culture, and prevent 
plucking-induced anagen in C3H/HeJ mice using OSM-soaked beads [203].  Yu et al also 
showed with immunohistochemistry that in human HFs, OSM was expressed in the IRS, ORS 
and DP, while its receptor OSMRβ was only localized to the ORS. Using the online resource 
HairGel.net, developed by the Rendl laboratory who used multicolor FACS to perform RNA-
sequencing on almost every cellular compartment in the skin of the mouse at P5 [8, 204], 
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OSMRβ and the co-receptor gp130 (gene name Il6st, see Box 1) are preferentially expressed in 
the epithelial compartment, particular the HFSCs, whereas OSM has in unknown cellular source 
in the dermis (Figure 1.5). Whether OSM is expressed in the skin of adult mice during the hair 
cycle is currently unknown. 
 
 
Box 1. OSM signaling nomenclature 
 
OSM – Oncostatin M 
 
OSMRβ – β-receptor for OSM, so named 
because it is recruited after OSM binds to 
gp130, gene name Osmr 
 
gp130 – co-receptor used by IL-6 family of 
cytokines, gene name IL6 signal transducer 
(Il6st) 
 
Type 1 OSM receptor –OSM can signal 
through the LIFRβ/gp130 heterodimer (in 
humans only) 
 
Type 2 OSM receptor – OSM signals 
through the OSMRβ/gp130 heterodimer (in 




Figure 1.6. Results from searches 
performed on Hair-Gel.net, an online 
resource by the Rendl laboratory that 
catalogues RNA-sequencing data 
from multiple compartments of mouse 
skin at E14.5 and P5 (Sennett et al, 
2015; Rezza et al, 2016). Data shown 
represents tissue distribution of 
OSMR, gp130 (Il6st) and OSM in the 
skin of a mouse at P5. OSMR is 
expressed mainly in the epidermal 
compartment, while OSM is 
expressed in the “neg” compartment, 
which includes unlabeled dermal cells 
that were not actively sorted (ie. 
immune cells, endothelial cells, 
smooth muscle cells). The gp130 co-
receptor is relatively ubiquitous in 
expression. Epi = epidermis, ORS = 
Outer root sheath, Mx = Matrix, Mc = 
melanocytes, DF = dermal fibroblasts, 
DP = all dermal papilla cells, TAC = 
transit amplifying cells, HF-ORS = 
ORS minus HFSC, ZZ-DP = DP of 
zigzag hair follicles, G-DP = guard 





1.5.3. OSM mediates quiescence via JAK-STAT signaling in various cell types 
 
In addition to its inhibitory properties on melanoma cell lines, OSM has been shown to have 
inhibitory effects on proliferation and differentiation in other systems. Like LIF, OSM is also able 
to inhibit differentiation of human ESCs [205]. In skeletal muscle, OSM prevents differentiation 
of myoblasts via the JAK1-STAT1-STAT3 pathway, and plays role in regulating muscle 
regeneration [206].  During mammary gland involution, OSM signaling via STAT3 also promotes 
remodeling by inducing epithelial cell apoptosis [207].  In human mammary gland epithelium, 
OSM-STAT3 signaling cooperates with Transforming Growth Factor (TGF)-β-SMAD3 signaling 
to induce senescence [208]. Interestingly, aged and senescent murine skin is also associated 
with increased JAK-STAT activity [209], although an upstream ligand for this effect has not been 
identified. 
 
OSM signaling via the JAK-STAT5 pathway inhibits adipogenesis and adipocyte terminal 
differentiation of 3T3-L1 and mouse embryonic fibroblasts (MEFs) treated with dexamethasone, 
insulin and 3-isobutyl-1-methylxanthine (IBMX) [210].  OSM also arrests HepG2 cells in the G1 
phase of the cell cycle via JAK-STAT5 signaling, which upregulates cyclin-dependent kinase 
(CDK) inhibitor p27kp1 that in turn reduces downstream CDK2 activity [211]. OSM via JAK-
STAT5 signaling also suppresses specific chemokine secretion in T cells [212].  
 
Global OSM-KO mice were found to have hematological discrepancies like anemia and 
thrombocytopenia, together with increased circulating PBMCs and decreased numbers of 
HSCs, suggesting a loss of quiescence in the HSC niche [213]. Otherwise, OSM-deficient mice 
developed normally and appeared indistinguishable from wild-type littermates, suggesting that 
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there were no gross hair or skin defects, and that OSM is not required for HF morphogenesis. 
The hair cycle was not closely studied in these mice. 
 
Together, these studies show that OSM signaling via the JAK-STAT pathway is a conserved 
and often employed for maintaining cellular quiescence in various contexts, making it a potential 




Our serendipitous observation that JAK inhibition in mouse skin was sufficient to initiate hair 
growth invited us to ask whether there is a JAK-STAT signal that mediates quiescence in the 
HFSCs. This inhibitory signal would fit the criteria for a chalone as described by Houck et al, 
and would be a potential therapeutic target for hair growth disorders associated with prolonged 
or arrested telogen. An extensive review of the literature suggests that members of the IL-6 
family of cytokines are ideal candidates for this chalone, and that dermal macrophages, which 
have been suggested to have important roles in the telogen-to-anagen transition, may be a 
source for this signal.  
 
AIMS OF THIS THESIS 
 
In this thesis, I asked the following questions: 
1. What is the upstream effector of JAK-STAT signaling in the HFSC during telogen? 
2. What is the source of this “chalone”? 




CHAPTER 2. ONCOSTATIN M IS PRODUCED BY TREM2+ MACROPHAGES AND 
MAINTAINS HAIR FOLLICLE STEM CELL QUIESCENCE DURING MURINE 
TELOGEN 
 
The mammalian hair cycle is a tightly coordinated process whereby the hair follicle undergoes 
distinct phases of growth (anagen), regression (catagen) and rest (telogen) [6]. Each phase of 
the hair cycle requires complex cellular interactions and molecular signals that directs the hair 
follicle stem cells (HFSCs), their epithelial progeny in the outer and inner root sheaths of the hair 
follicle (HF), and the instructional mesenchyme (the dermal papilla, DP) to produce or shed a 
hair shaft [7]. The keratinocytes of the HFSCs (located in the bulge and secondary hair germ, 
HG) receive activating signals, such as Wnt and Shh, that promote proliferation during anagen, 
and inhibitory signals, such as BMP, that promote quiescence during telogen. These signals are 
received from the microenvironment of the HF and may emanate from the DP or other cells 
types like the subcutaneous adipose tissue [39], and the K6+ inner bulge [40]. 
 
Cells of the immune system have been implicated in regulation of HFSC activity. For example, 
various classes of immune cells are recruited during depilation- and plucking-induced anagen 
(Table S1), and although these experimentally-induced anagen models are useful in studying 
anagen progression in the mouse, they do not give us much insight into immune cell regulation 
of the spontaneous hair cycle. The normal hair cycle is associated with significant alterations of 
the local immune cell composition [75], but these associations have been largely descriptive. 
Recently, macrophages have been shown to increase in numbers during early- and mid-telogen 





We have previously shown that pharmacological inhibition of JAK-STAT signaling is sufficient to 
induce anagen in “resting” telogen follicles in a manner analogous to physiological, spontaneous 
anagen [104]. This raises the question of whether JAK-STAT signaling is necessary for the 
maintenance of quiescence of HFSCs during telogen. So far, inhibitory signals during telogen 
have been attributed to BMP-2 (from the subcutaneous adipocytes) and BMP-4 (from within the 
hair follicle) [39], as well as BMP-6 and FGF-18 (from the K6+ inner bulge) [40]. However, none 
of these molecules are known to signal through the JAK-STAT signaling pathway. The upstream 
signal for JAK-STAT-mediated quiescence during telogen, if any, remains unknown. 
 
Oncostatin M (OSM) has been shown previously to inhibit plucking-induced anagen [137], while 
interleukin 6 (IL-6) has been shown to induce catagen in anagen follicles [131]. Both OSM and 
IL-6 belong to the gp130-dependent family of cytokines, which also includes leukemia inhibitory 
factor (LIF), cardiotrophin-1 (CT-1), ciliary neurotrophic factor (CNTF) amongst others. These 
cytokines signal via the JAK-STAT pathway, and the MAPK (mitogen-activated protein kinase), 
mTOR (mammalian target of rapamycin) and PI3K (phosphatidylinositol-3 kinase) pathways, to 
regulate a variety of biological processes, most notably stem cell maintenance and quiescence 
in a variety of tissue types [214, 215]. Thus, OSM, and/or the IL-6 family of cytokines, may be a 
potential chalone, or negative growth factor [2], in the mouse telogen skin. 
 
In this paper, we demonstrate that OSM maintains HFSC quiescence via JAK-STAT5 signaling 
in vivo, giving further insight to previous reports that OSM is associated with maintenance of the 
telogen state [137]. In addition, we identify a distinct subset of TREM2+ dermal macrophages as 






Oncostatin M maintains hair follicles in telogen via OSMR-JAK-STAT signaling 
 
We first tested OSM and other gp130 cytokines (IL-6 and Leukemia Inhibitory Factor, LIF) on 
their ability to inhibit anagen induced by topical JAK inhibitors, which has been described to 
resemble spontaneous anagen [104]. At P60, Ruxolitinib 2% (JAK1/2 selective inhibitor) in 
DMSO was applied topically to the right dorsal skin of C57BL/6 mice for five consecutive days. 
This treatment has been established in our lab to induce a robust anagen. Simultaneously, and 
for 5 additional days (for a total of 10 consecutive days), OSM, IL-6, LIF or PBS control was 
injected intradermally into a spot on the right dorsum of a P60 (mid-telogen) C57BL/6 mouse, in 
the middle of the field of topical Ruxolitinib (JAK1/2 selective inhibitor) application. Intradermal 
OSM was the only member of the gp130-dependent class of cytokines that inhibited anagen 
locally in the area where it was administered (Figure 2.1A).  
 
Conversely, intradermal injection into the dorsal telogen skin (P60) of neutralizing antibodies to 
the OSM receptor (OSMRβ) for 2 weeks produced the complementary effect of local anagen 
induction (Figure 2.1B). This effect was not observed with intradermal PBS or isotype IgG 
control. 
 
In order to assess the effects of OSM on HFSCs, ITGA6+ Sca-1- epidermal cells were isolated 
from telogen skin (Figure 2.2A, adapted from [216]), and were cultured and stimulated with 
increasing doses of OSM. OSM displayed a dose-dependent activation of the JAK-STAT1, JAK-
STAT3, JAK-STAT5 and MAPK-ERK pathways in cultured HFSCs in vitro (Figure 2.1C). OSM 
had minimal effects on the PI3K/Akt/mTOR pathway. Localization of pSTAT1 in vivo during  
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Figure 2.1. OSM prevents HFSC proliferation via OSMR-JAK-STAT5 signaling. A. C57BL/6 mice were treated on 
the right dorsal skin topically with Ruxolitinib 2% in DMSO at P60 for 5 days, recapitulating our previous experiments 
reported in Harel et al, 2015. This treatment regimen stimulates a robust anagen in the telogen skin that resembles 
the spontaneous, normal hair cycle. From P60, mice were also injected with control PBS or a gp130 cytokine (IL-6, 
LIF or OSM) into the middle of the field of topical application for 10 days. OSM was the only member of this family 
that was sufficient for preventing Ruxolitinib-induced anagen. Note that the lightness seen in the LIF-injected mouse 
is due to coat sheen rather than bare skin. Data from 2 independent experiments with n = 4 mice per group. B. 
Neutralizing antibodies to murine OSMRβ was injected intradermally into the center of the telogen back skin in P60 
C57BL/6 mice for 2 weeks. This was sufficient to induce a local anagen, while PBS and isotype IgG controls did not. 
Data from 3 experiments with n = 3 mice per group. C. Western blots performed on cultured HFSCs (ITGA6+ Sca-1-) 
exposed to OSM at 10ng/ml and 20ng/ml for 15 minutes. OSM activated JAK-STAT1/3/5 pathways and the MAPK-
MEK-ERK pathways in HFSCs, and had minimal effect on the PI3K/Akt/mTOR pathway. Pre-treatment with 
Tofacitinib inhibited the JAK-STAT and, to a lesser extent, the MAPK-MEK-ERK pathways. Total protein levels were 
not expected to change with short treatment times, and are not shown. D. Western blot of cultured HFSCs stimulated 
with OSM for 15 minutes, with or without pre-treatment with JAK inhibitors. OSM had a dose-dependent activation of 
all four JAKs (JAK1, JAK2, JAK3, Tyk2), as well as pSTAT3 and pSTAT5. Tofacinitib and Ruxolitinib pre-treatment 
inhibited phosphorylation of a variety of JAKs, and inhibited both pSTAT3 and pSTAT5 activation. PF-06651660, a 
specific covalent inhibitor of JAK3, did not have an effect on JAK1/JAK2/Tyk2 or STAT3 phosphorylation but still 
inhibited pSTAT5 activation. E. Clonogenicity assays of HFSCs. ITGA6+ Sca-1- epidermal stem cells were isolated 
by FACS, plated in 6-well plates, and cultured for 2 weeks. Addition of OSM 10ng/ml to the culture media completely 
prevented any stem cell colonies from forming, whereas the addition of Tofacitinib 100nM enhanced HFSC clone 
numbers, and also reversed the effect of OSM. (Data from 3 independent experiments) 
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telogen by immunofluorescence places its activity in the isthmus and infundibulum of the HF, 
and not the bulge/HG (Figure 2.2B). 
OSM signaling occurs through all four JAK kinases (JAK1, JAK2, JAK3 and Tyk2) (Figure 2.1D). 
These pathways were blocked with the addition of Tofacitinib (pan-JAK inhibitor). With the 
addition of a specific, covalent JAK3 inhibitor PF-06651600, we found that while different JAK 
inhibitors had varying effects on JAK1/2/3/Tyk2 and STAT3 phosphorylation, all of them resulted 
in potent pSTAT5 inhibition (Figure 2.1D). Notably, the covalent JAK3 inhibitor was able to 
initiate anagen with the 5-day topical treatment regimen previously described (Figure 2.2C), 
without significant inhibition of STAT3 phosphorylation in HFSCs. This suggests that inhibition of 
STAT5 phosphorylation, and not STAT3, in HFSCs is the common mechanism, and is sufficient 
to promote anagen initiation in mid-telogen skin. 
Colony-forming assays with isolated (ITGA6+ Sca-1-) HFSCs were performed in the presence 
of OSM (10ng/ml), Tofacitinib (100nM) or both (Figure 2.1E). OSM prevented HFSC colonies 
from forming in vitro, consistent with its inhibitory effect on hair growth. Tofacitinib increased the 
Figure 2.2. Supporting Data. A. Flow 
cytometric strategy for isolating HFSCs in 
the epidermis. All ITGA6+ cells are 
included, and Sca-1+ cells are identified as 
interfollicular epidermis. Sca-1- populations 
are associated with the HF. Of these, 
CD34+ cells represent the bulge, and P-
cadherinhi cells represent the hair germ 
(HG). B. pSTAT1 immunofluorescence 
during telogen. STAT1 signaling is not 
located in bulge (Bu) or (HG) HFSCs, but 
instead is localized to the isthmus and 
infundibulum of the HF (arrowheads). DP = 
Dermal papilla. Scale bar 50µm. C. Topical 
treatment with covalent JAK3 inhibitor PF-
06651600 induces anagen in telogen skin. 
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colony-forming ability of HFSCs, as well as increasing the colony size, consistent with previous 
reports [209]. The addition of Tofacitinib was also sufficient to rescue the inhibitory effects of 
OSM. These results suggest that OSM acts via JAK-STAT signaling, and most likely via 
activation of STAT5, to prevent proliferation of HFSCs, and is sufficient for maintaining HFSC 
quiescence during telogen in mouse skin. 
 
OSMRβ and its co-receptor gp130 are expressed on bulge and germ HFSCs, co-localizing with 
activated pSTAT5 during early- and mid-telogen 
 
In the mouse, OSM binds specifically to its receptor OSMRβ, which requires the co-receptor 
gp130 for signaling via the JAK-STAT pathway. We next sought to localize the expression of 
OSM, its receptor (OSMRβ) and co-receptor (gp130). By separating the mouse dorsal skin into 
the epidermal and dermal compartments with 0.25% trypsin and performing qRT-PCR for 
OSMRβ and OSM, we showed that OSMRβ was distinctly expressed in the epidermal fraction 
(which contains the epithelial parts of hair follicles), whereas OSM was located in the dermal 





Figure 2.3. Spatiotemporal distribution of OSM signaling apparatus during hair cycle. A. Trypsin-dissociated 
epidermal and dermal tissue from P60 C57BL/6 mice were subjected to qRT-PCR for OSMRβ and OSM. The 
epidermal sheet contains the hair shafts, whereas the DP was retained with the dermal fraction. The epidermal 
fraction is enriched for OSMRβ (p < 0.0001), while the dermal fraction is enriched for OSM (p=0.21). A clear dermal-
epidermal signaling axis for OSM is demonstrated. (n = 3 mice) B. Flow cytometric analysis of the epidermal ITGA6+ 
stem cells into IFE (Sca-1+), bulge (CD34+) and HG (P-cadherin+). qRT-PCR for Keratin 17 (hair shaft keratin) was 
performed to confirm the sorting strategy. OSMRβ and gp130 are expressed at higher levels in the HFSCs of the 
bulge and HG. (n = 3 mice) C. qRT-PCR array of JAK-STAT genes across the hair cycle (adapted from Harel et al, 
2015). STAT5a/b and STAT3 expression peak during telogen. D. Western blot for pSTAT5 in isolated epidermis 
across the hair cycle. Consistent with the qRT-PCR array data, pSTAT5 activation peaks during telogen (Tel), more 
prominently in during early- and mid-second telogen (P42-P60). Ana = Anagen. (n = 1 mouse per timepoint) E. qRT-
PCR for OSM in isolated dermis across the hair cycle. OSM levels peak from early-mid telogen in C57BL/6 mice. (n = 
2 mice per timepoint) Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p<0.0001, (A) Student’s unpaired 




To further define the expression of OSMRβ and gp130, the epidermal fraction was separated by 
fluorescence activated cell sorting (flow cytometry or FACS) into the Sca-1+ interfollicular 
epidermis (IFE), CD34+ bulge, and the P-cadherin+ hair germ (HG) (Figure 2.2A). qRT-PCR for 
Keratin 17 (a differentiated HF keratin) validated this sorting strategy with an increasing 
expression of Krt17 from IFE->Bulge->HG (Figure 2.3B). qRT-PCR confirmed that OSMRβ and 
gp130 were preferentially expressed in the bulge and HG telogen HFSCs. This was confirmed 
with immunofluorescence (Figure 2.4A). Of note, gp130 is also expressed in many other cell 
types in the dermis. 
 
 
In keeping with our previous qRT-PCR array data showing dynamic STAT5 activity over telogen 
(Figure 2.3C) [104], we show with Western blotting of isolated epidermal sheets that activated 
pSTAT5 protein is also dynamically expressed in the epidermis across telogen, peaking at mid-
telogen around P56-P60 (Figure 2.3D). Using immunofluorescence studies, we show that 
Figure 2.4. Immunofluorescence of OSMRβ 
and gp130 in telogen HF.  
A. Immunofluorescence of P60 telogen hair 
follicle showing co-localization of OSMRβ and 
gp130 in the HFSC compartment, marked with 
the stem cell marker Keratin 15. Note that 
gp130 expression is ubiquitous, but strong in 
the HG. OSMRβ expression is also expressed 
in scattered dermal cells. Scale bar 25µm. B. 
Immunofluorescence of pSTAT5 across the hair 
cycle. Activation of pSTAT5 localizes to the 
HFSC compartment particularly strongly from 
P42-P60, which represents early-to-mid second 
telogen, and is diminished in the first telogen 
(P26) and late second telogen (P80), when the 




pSTAT5 during early- and mid-telogen is localized prominently in the bulge and HG HFSCs 
(Figure 2.4B). pSTAT5 expression in the HFSC decreases by the end of telogen (P80), in 
agreement with recent publications [124]. This peak of pSTAT5 activity in the HFSC coincides 
with a peak of OSM expression in the dermis, measured with qRT-PCR (Figure 2.3E). These 
data show that elevated OSMRβ-pSTAT5 signaling in HFSCs is correlated with early- and mid-
telogen, and decreases during late telogen. 
 
Genetic ablation of OSMRβ before early telogen delays and shortens the second telogen 
 
To examine the significance of OSMRβ and pSTAT5 localization to telogen hair follicles, we 
generated C57BL/6 mice with K5-CreERT2 transgenes coupled with either OSMRβFL/FL or 
STAT5a/bFL/FL alleles. Mice were closely shaved with clippers to allow for direct visualization of 
the dorsal skin, which appears uniformly pink during the synchronized second telogen (P45-
P100), and darkens in tandem with the entry into anagen when melanocytes proliferate. 
Systemic administration of tamoxifen was carried out during early-to-mid telogen to genetically 
ablate either OSMRβ or STAT5 in epidermal stem cells, including the HFSC. OSMRβ and 
STAT5 conditional knock-out was confirmed with qRT-PCR, Western blot and 
immunofluorescence studies (Figures 2.5A-E). Interestingly, epidermal OSMRβ ablation was 





When we ablated OSMRβ or STAT5 at P35-P38 (end of anagen, just before catagen), we found 
that the upcoming second telogen, which typically lasts 40-60 days in the C57BL/6 mouse, was 
drastically shortened to less than 2 weeks (Figure 2.6A). Interestingly, in the K5-
CreERT2::STAT5a/b
FL/FL mice, despite close shaving, their dorsal skin remained dark and 
pigmented, suggesting the persistence of the anagen phase (Figure 2.6A – last row). With 
pigmentation of shaved dorsal skin as a surrogate for anagen, K5-CreERT2::OSMRβFL/FL and 
K5-CreERT2::STAT5a/b
FL/FL mice appeared not to enter full telogen as did their wild-type 
Figure 2.5. Validation of OSMRβ and STAT5 conditional KO. A. qRT-PCR for OSMRβ in the hair follicle of K5-
CreERT2::OSMRβFL/FL mice. HFSCs include bulge and HG cells (ITGA6+ Sca-1-). B. Western blot of whole 
epidermis in K5-CreERT2::OSMRβFL/FL mice showing reduced expression of OSMRβ after Tamoxifen induction. C. 
Immunofluorescence studies of telogen HFs in WT and K5-CreERT2::OSMRβFL/FL mice. K5-CreERT2::OSMRβFL/FL 
mice had reduced expression of OSMRβ in the bulge and HG, coupled with reduced pSTAT5 activity in the HFSCs. 
pSTAT5 expression in the DP remained unchanged. Scale bar 50µm. D. qRT-PCR for STAT5a and STATb in K5-
CreERT2::STAT5a/bFL/FL mice, in the bulge and germ at +10 and +20 days post-tamoxifen. STAT5a/b expression 
continued to decrease from +10 to +20 days likely because cells with reduced STAT5a/b began to proliferate and 
predominated the HFSC compartment. D. Immunofluorescence studies for pSTAT5 in WT and K5-
CreERT2::STAT5a/bFL/FL mice 20 days after Tamoxifen induction. Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p 
< 0.001, ****p<0.0001. Student’s unpaired t-test. 
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littermates (Figure 2.6B). This was confirmed with histology at P60, when control wild-type 
littermates had small telogen HFs that had retracted entirely within the dermis, both 
homozygous mutant mice for OSMRβ and STAT5a/b were in anagen (Figure 2.6C). 
 
Figure 2.6. Early telogen ablation of OSMRβ/STAT5. A-B. Conditional knock-out of either the OSMRβ or the 
STAT5 gene using the K5-CreERT2 driver before the early telogen resulted in a much shortened telogen phase. 
STAT5 ablation during catagen prevented HFSC from reaching full quiescence. Anagen quantification was performed 
using threshold analysis of the dorsal skin color in ImageJ, since darkening of the skin due to melanogenesis is 
coupled closely to anagen progression. Mice were closely shaved one day before acquisition of pictures to ensure a 
close view of the epidermal color. Results are representative of 5 litters for each gene (OSMRβ or STAT5), with 2-5 
mice per litter, for a total of 17 mice for OSMRβ (5 homozygous OSMRβFL/FL) and 18 mice for STAT5 (5 homozygous 
STAT5FL/FL). Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p<0.0001; Two-way ANOVA between 
genotypes at each respective timepoint C. H&E examination of WT, K5-CreERT2::OSMRβFL/FL mice. K5-
CreERT2::OSMRβFL/FL mice which underwent Tamoxifen induction at P35-P38. At P60, when WT littermates were 
well into telogen, mice lacking OSMR or STAT5 in their epidermal compartments were well into their next anagen 
phase. Scale bar 100µm. 
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Genetic ablation of OSMRβ and STAT5 during telogen in the epidermis promotes HFSC 
proliferation and anagen initiation 
 
Using genetic means to recapitulate the pharmacological effect of JAK-inhibition in mouse 
telogen skin, tamoxifen induction was carried out during mid-telogen (P56-P60) over a period of 
4 days to conditionally knock-out either OSMRβ or STAT5 in the epidermis and hair follicle. Both 
K5-CreERT2::OSMRβ
FL/FL and K5-CreERT2::STAT5a/bFL/FL mice entered anagen significantly 
earlier than their wild-type or heterozygous littermates (Figure 2.7A), approximately 3 weeks 
after tamoxifen induction. Quantification of anagen initiation was carried out by the darkening of 
the dorsal skin of C57BL/6 mice, an event that is closely coupled to anagen induction (Figure 
2.7B) [6]. Genetic ablation of OSMRβ or STAT5 in the epidermis and hair follicle after P60 did 
not result in significantly earlier anagen induction (data not shown), suggesting OSMRβ-JAK-





We next studied the cellular dynamics that result from genetic ablation of JAK-STAT5 signaling, 
since this was the most downstream element of the pathway, and the anagen-inducing effect of 
STAT5-ablation was stronger in Figure 2.7B. K5-CreERT2::STAT5a/bFL/FL mice and their control 
littermates were induced with tamoxifen during mid-telogen. Since anagen initiation in the 
STAT5FL/FL mice occurred around 3 weeks after tamoxifen induction, we bisected this period to 
observe the early responses of the HFSCs with STAT5 ablation. Cellular proliferation was 
studied at 10 and 20 days post-tamoxifen with EdU administration 24 hours before the mice 
were sacrificed. At 10 days post-tamoxifen induction, cellular proliferation was observed in the 
HG, while the bulge remained quiescent (Figure 2.8A). After 20 days, the proliferation in the HG 
was even more prominent, and EdU incorporation was also seen in the lower bulge, but this 
latter effect was not significant (Figure 2.8B). 
Figure 2.7. Mid telogen ablation of OSMRβ/STAT5. A. Conditional knock-out of OSMRβ or the STAT5 at P56-P60 
(mid-telogen) resulted in early anagen initiation (K5OSMR or K5STAT5) compared to control littermates. B. Anagen 
progression was quantified as described earlier. Results are representative of 4 litters for each gene (OSMRβ or 
STAT5), with 2-4 mice per litter, for a total of 11 mice for OSMRβ (4 homozygous OSMRβFL/FL) and 12 mice for 
STAT5 (4 homozygous STAT5FL/FL). Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p<0.0001; Two-





By FACS, the P-cadherin+ HG cells significantly double (from approximately 0.3% of total 
epidermal cells to 0.6%) at +10 days post-tamoxifen (Figure 2.8C). Furthermore, comparing the 
relative increase in cell numbers between the bulge and HG after STAT5 ablation, the HG 
proliferates up to 8-fold, while the cell numbers of the bulge stay relatively constant (Figure 
2.8D). This initial proliferation in the HG is consistent with previous reports of the pattern of 
HFSC activation during spontaneous anagen [52], as well as the pattern observed with the 
administration of topical JAK-inhibitors [104]. These genetic data are in agreement with our 
previous pharmacological inhibition experiment, and further support the hypothesis that 
Figure 2.8. Cellular dynamics following STAT5 epidermal ablation. A. EdU incorporation was analyzed +10 and 
+20 days (D10 and D20) after tamoxifen induction in K5-CreERT2::STAT5FL/FL mice (cKO). EdU (4mg/25g adult 
mouse) was injected 24 hours before sacrifice. At D10, STAT5 epidermal ablation, EdU incorporation is seen in the 
HG, while the bulge remained quiescent. At D20, occasional EdU+ cells were seen in the bulge, and the HG was 
even more proliferative. Scale bar 25µm. B. Quantification of proliferative cells (EdU+) in each hair follicle 
compartment: P-cad+ HG (Germ), CD34+ Bulge or Isthmus/Infundibulum (I/I) after tamoxifen induction of STAT5-
ablation in WT and K5-CreERT2::STAT5FL/FL littermates. CD34-negative cells above the bulge but within the HF were 
considered I/I. EdU incorporation was observed in the HG by D10 (n.s.), which became significant by D20. At D10, 
bulge proliferation was minimal, and slightly increased at D20. (Data points are mean of 20 HFs per mouse, n = 3 
mice per genotype) C. Flow cytometric quantification of stem cell populations. At +10 days after STAT5 ablation, the 
percentage of total ITGA6+ Sca-1- CD34- Pcad+ cells (HG) doubled from 0.3% of total epidermis to 0.6% epidermis. 
(n = 3 mice per genotype) D. While the cell population in the bulge remained relatively constant after epidermal 
STAT5 ablation, the HG population proliferated and expanded exponentially with the loss of STAT5 signaling. (n = 3 
mice per genotype) Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p<0.0001; (B,D) Two-way ANOVA 
of cellular compartment between genotypes at D10 and D20. (C) Student’s t-test. 
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OSMRβ-JAK-STAT5 signaling is necessary for maintaining HFSC quiescence during murine 
telogen, specifically during the refractory period of telogen (early-to-mid telogen).  
 
Dermal OSM is produced by tissue-resident macrophages during telogen 
 
We next aimed to define the source of OSM, which was shown in Figure 2.3A to be expressed 
within the dermal fraction (containing the DP). Performing qRT-PCR on isolated dermis tissue 
collected across the murine hair cycle, we found that Osm transcripts peaked in mid-telogen 
(Figure 2.3E), which is in sync with the expression of pSTAT5 seen in Figure 2C, consistent with 
its postulated function in maintaining HFSC quiescence. Since previous reports suggested that 
the human dermal papilla (DP) may be the source for IL-6 [137], we first employed laser-capture 
microdissection (LCM) to isolate the DP to locate Osm transcripts. Perifollicular dermal tissue, 
primarily containing dermal fibroblasts (DF) but not DP, was used as a control. However, we did 
not detect any Osm transcripts in the DP or DF samples with this method, even though DP-
specific LEF1 was found in the DP, and COL1A1 was found enriched in both dermal populations 
as expected (Figure 2.9). 
 
 
Figure 2.9. Laser-capture microdissection of DP and 
perifollicular dermal tissue containing fibroblasts (DF) to 
determine the source of OSM by qRT-PCR. While DP 
(green dotted line) samples were rich with Lef1 and 
Col1a1 mRNA, no OSM was detected. DF tissue (blue 
dotted line) contained Col1a1 mRNA but not Lef1 or Osm. 
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We next used RNAscope multiplex in situ hybridization to localize the source of OSM. In telogen 
skin, the transcripts for OSMR and its co-receptor (gp130, gene name Il6st) were found 
predominantly within the hair follicle, consistent with previous findings. Since OSM could not be 
detected in the perifollicular dermal tissue by LCM, we reasoned that OSM must be produced by 
scattered, possibly migratory cells, of the immune system. Referring to Hair-GEL.net, OSM 
appeared to be expressed in the “Neg” population of skin cells, which includes immune cells, 
smooth muscle cells and endothelial cells of the dermis [8, 204]. In agreement with these 
findings, we found that Osm transcripts were found scattered in the dermal tissue adjacent to 
the hair follicle, rather than within the DP (Figure 2.10A-B). 
 
Figure 2.10. Identifying the source of OSM as dermal macrophages. A. Multiplex fluorescence in-situ 
hybridization (RNAscope) for Osm, Osmr and Il6st (gene for gp130). Osm mRNA was detected most frequently in 
perifollicular dermal regions (white arrows). Osmr and Il6st mRNA was generally found in the hair follicle 
keratinocytes. B. Quantification was performed over 21 imaged follicles in a 20x field from 2 mice in early-mid 
telogen. Each row represents one HF, and shaded bars represent the distribution of fluorescent particles within or 
around the HF as outlined by DAPI nuclear staining of the HF and DP converted to a percentage of total particles in 
the 20x field. C. Flow cytometric analysis of telogen dermis to separate DP (ITGA9+) and macrophages (CD45+ 
F4/80+ CD11b+). qRT-PCR for OSM revealed that dermal macrophages (F4/80+ CD11b+) were the main source of 
OSM. DPs and CD11b- immune cells were generally negative for OSM. (n = 3 mice) D. Flow cytometric analysis of 
inflammatory (MHC II+) and non-inflammatory, tissue resident (CD163+) macrophages during telogen. qRT-PCR of 
macrophage subsets isolated by this FACS strategy confirmed that CD163+ “M2-like” non-inflammatory 
macrophages were the main source of OSM in the dermis. (n = 3 mice) 
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Since tissue macrophages were recently reported to have a role in maintaining the second 
murine telogen [89], we postulated that these cells may be the source of OSM. Using FACS, we 
sorted the telogen dermis for macrophages (CD45+ F4/80+ CD11b+). Using qRT-PCR, the non-
macrophage immune cells (CD45+ F4/80- CD11b-) and presumptive DP (CD45- ITGA9+, 
identified using the online resource Hair-GEL.net [8, 204]) were mostly negative for OSM. By 
qRT-PCR, macrophages (CD45+ F4/80+ CD11b+) were found to be the main source of dermal 
OSM (Figure 2.10C). Using CD163 and MHC II as markers for M2 and M1 markers respectively, 
we also found OSM to be enriched in the “M2-like” CD163+ MHC IIlow macrophage subset 
(Figure 2.10D).  
Single-cell RNA-sequencing of dermal CD45+ immune cells 
Although we found that “M2-like” macrophages were enriched for OSM-producing cells in vivo, 
we sought to account for the heterogeneity of tissue macrophages by performing single-cell 
RNA sequencing on the dermal CD45+ immune cells during early (P45), mid (P50, P63) and 
late (P80) telogen. This provided us with an unbiased survey of the immune cells across 
telogen. Analysis of CD45+ immune cells during early telogen (P45) revealed 13 distinct 
clusters, which represent the main components of the immune infiltrate in unperturbed mouse 
early telogen skin (Figure 2.11A). At P45, macrophages clustered into 5 distinct clusters: 0, 1, 2, 
5 and 11 (Figure 2.11A – dotted circle). OSM itself was significantly upregulated in a distinct 
cluster (cluster 11) (Figure 2.11B). 
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Next, we re-analyzed the data focusing on the macrophage clusters to produce a new set of 
clusters (Figure 2.11C-D). These macrophage-only clusters showed relatively uniform CD68 
expression, but M1 and M2 markers were unevenly expressed amongst the clusters (Figure 
2.11E), reflecting the macrophage heterogeneity of the unpolarized and unperturbed dermis at 
Figure 2.11. P45 single-cell RNA sequencing. A. Single-cell RNA-sequencing of CD45+ dermal immune cells at 
P45 (early telogen). CD45+ cells were isolated with flow cytometry and 2145 cells were analyzed using the 10x 
Genomics platform. Macrophages (defined by markers CD68, Csf1r, F4/80) clustered into 5 distinct clusters (0, 1, 2, 
5, 11, circled with dotted line in B). B. OSM was enriched in cluster 11 (circled in G). C-D. Clustering of just the 
macrophage populations yielded seven distinct subsets, with OSM production enriched in cluster 6 of this re-analysis. 
E. Visual inspection of known macrophage markers and M1/M2 markers show that there is significant heterogeneity 
of macrophages in unperturbed mouse telogen skin. Clusters 0 and 1 tend to express more “M1-like” markers, while 
clusters 2 and 3 expressed more “M2-like” markers. Cluster 6, where OSM is enriched, does not fall clearly into either 
M1 or M2 markers based on conventional markers. Note Adgre1 = F4/80; Mrc1 = CD206. 
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this stage of the hair cycle. OSM expression was significantly higher in cluster 6 macrophages 
(Figure 2.11D), which did not conform to a classic M1 or M2 gene expression profile. 
OSM-producing macrophages have a distinct gene-expression profile 
Comparing the genes expressed by each cluster in a heatmap, cluster 6 macrophages most 
resemble the “M2-like” macrophages of cluster 3 (Figure 2.12). Interestingly, TREM2 is a 
distinguishing gene between these two sets, being highly expressed by cluster 6 OSM-




















































































































































































































Analyzing the enriched genes of cluster 6 (Figure 2.13A, Appendix C) with the online resource 
Enrichr  (http://amp.pharm.mssm.edu/Enrichr/), we found that this set of genes were 
significantly associated with microglia (Appendix D), which are the long-term tissue-resident 
macrophages of the central nervous system. Established microglial markers such as Apoe, Aif-1 
(Iba-1), Cx3cr1 and Tmem119 were all found to be expressed at varying levels in the OSM-
producing macrophages, and TREM2 was found to be the most specific marker for this set of 
macrophages (Figure 2.13B).  
Figure 2.13. OSM-producing macrophages resemble microglia. A. Enrichr analysis of most enriched genes in 
cluster 6 suggest that these genes are also enriched in microglia, according to the Mouse Gene Atlas. B. Microglial 
markers have different distributions amongst the dermal macrophages. C. Violin plots of gene expression across 
macrophage subsets. Cluster 3 tends to have more M2 markers (Mrc1 = CD206; CD163), while clusters 0 and 1 are 
more enriched in M1 markers like IL-1b, TNF and MHC II (H2-Ab1). Microglial markers ApoE and TREM2 are co-
expressed in cluster 6 macrophages along with OSM, with TREM2 being the most specific to this population. 
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OSM-producing macrophages are TREM2+ and resemble M2 macrophages 
 
Analyzing the macrophage markers in the macrophage clusters, OSM and TREM2 expression 
were found to be highly specific for cluster 6 (Figure 2.13C). Cluster 3 macrophages were 
relatively enriched for M2 markers Mrc2 (CD206) and CD163, while clusters 0 and 1 were more 
enriched for M1 markers like IL-1b and MHC Class II (H2-Ab1). 
 
Due to their similarities in gene expression on the heatmap in Figure 2.12, and their proximity in 
clustering in Figure 2.11C, clusters 6, 5 and 3 were analyzed further for their relationships in 
pseudotime. Multidimensional scaling of the clusters was performed, and these clusters formed 
a potential differentiation trajectory (Figure 2.14A). Microglial markers and OSM were also 
expressed dynamically across these clusters (Figure 2.14B). Assuming the macrophage 
heterogeneity in the dermis reflects varying differentiation states of tissue-resident 
macrophages, this model suggests that TREM2+ OSM-producing macrophages (cluster 6) may 








TREM2+ OSM-producing macrophages are closely associated with HFSC 
 
Immunofluorescence studies were carried out with the microglial markers identified in this 
distinct subset of macrophages. Aif-1, which were expressed in most macrophages at P45, was 
found to co-localize with CD11b and OSM, in immune cells that surround the hair follicle at P45 
(Figure 2.15A). TREM2, which was specific for the OSM-producing subset, was also found to 
co-localize with F4/80 and OSM in close approximation to telogen HFSCs (Figure 2.15B). These 
data strongly suggest that OSM is produced by a distinct subset tissue macrophage that is 




Figure 2.14. Pseudotime analysis 
A. Multidimensional scaling (MDS) of 
P45 macrophage clusters. 
Macrophage clusters 6, 5 and 3 were 
selected due to their proximity on the 
tSNE plot in Figure 2.11C. 
Arrangement of clusters in the MDS 
plot suggests cellular transition from 
clusters 6  5  3. B. OSM and 
microglial markers shown according 
to their expression within this MDS 
plot. This proposed cellular transition 
is associated with downregulation of 
OSM and TREM2, and also a 
general downregulation of microglial 
markers. C. Pseudotime analysis of 
OSM and microglial markers in these 
macrophages suggest a 
differentiation pathway for TREM2+ 
trichophages into “M2-like” 
macrophages, which is accompanied 




TREM2+ macrophages decrease over telogen 
 
Dermal tissue was collected from C57BL/6 mice at 3 other timepoints during telogen, and 
analyzed with single-cell RNA sequencing (Figure 2.16A). The CD45+ immune cell diversity in 
the dermis decreases as telogen progresses, starting with 13 distinct clusters at P45, and falling 
to 3 clusters by P63. The OSM-producing cluster, while distinct at P45, becomes less distinct at 
P50, and is greatly diminished by P63 and P80 (Figure 2.16B). 
 
Using FACS, TREM2+ macrophages in the dermis were found to be prominent during early- 
and mid-telogen, and were greatly reduced in number by late-telogen (Figure 2.16C), consistent 
with our observations of the scRNA-seq data.  
Figure 2.15. OSM-producing macrophages are associated with telogen HFs. A. Immunofluorescence of Aif-1, a 
microglial marker, that co-localizes with CD11b and OSM, surrounding a telogen HF. B. Immunofluorescence of TREM2, 
a specific marker for the OSM-producing macrophages, co-localizing with F4/80 and OSM, surrounding the HFSC of a 





When cells from all telogen timepoints are pooled and analyzed together, the microglia-like cells 
from P45 cluster distinctly (Figure 2.17A-B), suggesting that these cells are unique to early 
telogen, and are somehow lost as telogen progresses. When the pooled data is labelled 
according to the 4 telogen timepoints, early, mid and late telogen have overlapping but quite 
distinct immune cell profiles (Figure 2.17C). While this dynamism of immune cells across 
telogen has been described anatomically [75], this is the first functional correlation of this 
phenomenon.  
Figure 2.16. TREM2+ macrophages numbers decrease over telogen. A. Single-cell RNA sequencing was 
performed at 3 further timepoints in telogen (P50, P63, P80). Number of cells at each time point analyzed were 1497 
(P50), 592 (P63) and 497 (P80). Immune cell diversity becomes less diverse as telogen progresses. B. The OSM-
producing cluster becomes less distinct as telogen progresses. At P50, OSM producing macrophages are dispersed 
in the main macrophage cluster, and by P63, very few cells express OSM. C. Flow cytometry of dermis across 
telogen using TREM2. Macrophages (gated on CD45, F4/80 and CD11b) were further analyzed according to their 
TREM2 and MHC II expression. TREM2+ macrophages tend to be MHC IIlow, as expected, and their numbers 
decrease from early to late telogen. D. Schematic of telogen HF with TREM2+ macrophages that produce OSM, 





Analyzing the trajectories of OSM and microglial markers across telogen, we find that all these 
genes decrease with time (Figure 2.17D), being most prominent at early-to-mid telogen. Along 
with our FACS data, these data support the disappearance of the TREM2+ subset of 





Figure 2.17. Combined scRNA-seq data across telogen. A. tSNE plot of pooled data from CD45+ dermal cells of 
C57BL/6 mice at P45, P50, P63 and P80. B. Cluster 6 macrophages (microglia-like cells, mgl) cluster distinctly when 
pooled with all timepoints. C. Same plot highlighting the different timepoints. The profiles of CD45+ immune cells in 
the dermis throughout telogen is dynamic and shifts with time. D. OSM, TREM2 and other microglial markers 
decrease across telogen in the dermis. 
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Depilation during telogen causes loss of TREM2+ macrophages 
 
As depilation during telogen is known to induce synchronized anagen across the dorsal skin, we 
next interrogated the effect of depilation on TREM2+ macrophages. P50 C57BL/6 mice were 
treated with depilatory cream, and dermal CD45+ immune cells were analyzed by scRNA-seq 5 
days later, before any darkening of the dorsal back skin is evident (Figure 2.18A). While the 
diversity of immune cells at this timepoint (P50 depilation + 5D) was comparable to that of 
unperturbed P50 immune cells, the fraction of TREM2+ macrophages and OSM expression was 
reduced to the levels of late telogen P80 skin (Figure 2.18B-C). These data further support the 
hypothesis that downregulation of OSM, and reduction in the number of TREM2+ macrophages, 
are associated with anagen initiation.  
 
 
Figure 2.18. Depilation causes 
decrease in OSM-producing 
macrophages. A. tSNE plots of 
CD45+ dermal immune cell 
clusters of P50 skin before 
depilation, and P50 skin 5 days 
after depilation. Dotted lines 
encircle macrophage clusters. B-
C. OSM, TREM2 and Tmem119 
expression in dermal immune cells 
are reduced 5 days after depilation 
(n = 1502 cells). Levels of OSM 
are reduced to levels comparable 
with late telogen P80 skin. Unlike 
at the P45 timepoint, most 
TREM2+ macrophages at this time 
point appear to have 
downregulated OSM production. 
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T regulatory cells (T regs) have recently been shown to play a role in depilation-induced anagen 
[83], were dispensable for these effects (Figure 2.19A-B). Interestingly, while spontaneous 
anagen was associated with a decrease in FoxP3- and TNF-producing cells in our single-cell 
RNA-seq data (the latter being implicated in plucking-induced anagen [82]), depilation of telogen 
skin did not significantly reduce the expression of these cell populations (Figure 2.19C). These 
data suggest that while both experimentally-induced and spontaneous anagen are associated 
with loss of OSM and TREM2+ macrophages, they are mechanistically distinct with respect to 










Figure 2.19. T-regulatory cell depletion does not affect JAK-STAT induced anagen. A. T reg depletion with anti-
CD25 neutralizing monoclonal antibody (PC61). C57BL/6 treated with 3 intraperitoneal injections of PC61 exhibited 
marked T reg depletion in the spleen and dermis. B. Mice treated with PC61 underwent JAK-inhibitor initiated anagen 
with the same kinetics as WT mice. Likewise, mice treatment with the small molecule Csf1r tyrosine kinase inhibitor 
Pexidartinib to target macrophages also underwent anagen initiation. Together, these data demonstrate that these 
processes are not dependent on T regs. C. Depilation does not affect the levels of FoxP3 or TNF expression in the 
dermal immune cells. FoxP3+ T regs and TNF-producing macrophages have been implicated in experimentally-
induced anagen. These cell populations decrease at unperturbed P80 skin, highlighting differences between 
experimentally-induced and spontaneous hair cycling. 
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Macrophage inhibition during telogen leads to anagen initiation 
 
We used three independent methods of macrophage inhibition during telogen to initiate anagen 
in C57BL/6 mice. Neutralizing antibodies to Csf1r (AFS98) and F4/80/EMR1 (CI:A3-1) have 
been shown to preferentially deplete tissue resident populations of macrophages [217, 218]. 
Neutralizing antibodies to Csf1r and F4/80 (Figure 2.20A), topical and subcutaneous 
Pexidartinib (PLX3397, Csf1r tyrosine kinase inhibitor) (Figure 2.20B) were both successful at 
initiating anagen when administered during mid-telogen. 
  
We also bred a Csf1r-CreER mouse with Rosa26-iDTR (R26-iDTR) mice, producing offspring 
that will express the diphtheria toxin receptor on Csf1r+ cells upon tamoxifen induction. 
Tamoxifen was administered for 4 days in mid-telogen, followed by 7 days of intradermal 
diphtheria toxin (DTA) injections. This treatment led to ablation of dermal macrophages, and 
resulted in local anagen initiation that preceded their the wild-type littermates that received the 
same DTA injections (Figure 2.20C). Introduction of the R26-TdTomato reporter allowed us to 
demonstrate macrophage ablation in these mice. Analysis of biopsies of the dorsal skin 10 days 
after intradermal DTA show a drastic reduction in perifollicular TdT+ macrophages in the area of 
intradermal DTA injection, and this was associated with increased EdU incorporation of HFSCs 
(Figure 2.20D). Ablation of HF-associated macrophages was strongly correlated with increase 
HFSC proliferation (Figure 2.20E). Flow cytometry of the dermis dissected from these areas 
also show preferential ablation of the F4/80+ TREM2+ subset of macrophages (Figure 2.20F), 




These data, along with previously published findings by others [89], strongly support the 
hypothesis that macrophages are necessary for the maintenance of an inhibitory environment 





Macrophage OSM inhibits hair regeneration 
 
To examine the interactions between macrophages and HFSC in more detail, we used hair 
reconstitution assays to show that macrophages had an inhibitory effect on hair regeneration. 
Neonatal keratinocytes and dermal cells were injected intradermally in a 1:2 ratio in the patch 
assay, which recapitulates the epithelial-mesenchymal interactions required for HF 
regeneration. While tofacitinib enhanced the hair follicles generated in this assay, consistent 
with our previous findings [104], addition of OSM was sufficient to nearly completely inhibit hair 
reconstitution. Macrophages sorted from the P60 telogen dermis were recombined with the 
neonatal cells, and these were also found to inhibit hair reconstitution (Figure 2.20G).  
 
Figure 2.20. Macrophage depletion during telogen initiates anagen, and OSM knock-down prevents the 
inhibitory effects of macrophages on HFSC. A. Neutralizing antibodies to Csf1r and F4/80 injected intradermally 
into the middle of the dorsal skin of C57BL/6 mice for 14 days were sufficient to initiate a local anagen at the site of 
injection. B. Pharmacological inhibition of Csf1r (5 day treatment) with the small molecule Pexidartinib was similarly 
successful at initiating anagen when administered both topically and subcutaneously. C. Genetic ablation of 
macrophages using Csf1r-CreER::R26-iDTR mice. Tamoxifen was administered systemically for 4 days from P53-
P56, and 10ng diphtheria toxin (DTA) was injected intradermally for 7 days from P60. A local anagen was initiated at 
the site of injection. D-E. Csf1r-CreER::R26-TdTomato::R26-iDTR mice and littermate controls (no R26-iDTR) 
underwent Tamoxifen induction and DTA administration as described. Dermis from area of injection, and a remote 
area on the dorsal skin, were collected and examined with IF and FACS. Intradermal DTA was associated with loss of 
perifollicular macrophages in mice expressing iDTR on macrophages, which in turn was associated with increased 
proliferation of HFSCs highlighted by increased EdU incorporation. (Quantification of 50 HFs in a 20x field across 2 
mice. R2 = 0.4674, p<0.0001. Dotted lines represent 95% CI.) F. FACS of dorsal skin at the site of intradermal DTA 
treatment compared with remote areas, and with control mice (no R26-iDTR). Local DTA injection resulted in 
reduction of all macrophages (with reduced density seen in the FACS plot), and specific ablation of the F4/80+ 
TREM2+ subset of macrophages. Reduction of TREM2+ macrophages in the remote area (0.58%) of Csf1r-
CreER::R26-TdTomato::R26-iDTR mice might be a reflection of DTA diffusion. Data representative of 2 experiments. 
G. Patch assay for hair reconstitution. Neonatal epidermis and dermis were recombined to assess the effect of 
macrophages and OSM on hair reconstitution. Addition of Tofacitinib 100nM enhanced hair regeneration in this 
model. Addition of OSM 20ng/ml completely inhibited hair regeneration. F4/80+ CD11b+ macrophages (MP) sorted 
from adult telogen dermis also inhibited hair regeneration. Data from 3 patches per condition, across 2 independent 
experiments. H. shRNA knockdown of OSM in cultured peritoneal macrophages. Macrophages were obtained from 
murine peritoneal cavity with gavage and cultured in the presence of M-CSF to skew them to an anti-inflammatory 
phenotype. Plasmids containing shRNA (scrambled or OSM-specific) were transfected into the macrophages and 
OSM knock-down was confirmed by qRT-PCR. Data from 2 independent transfections. I. Patch assay with OSM 
knock-down. While macrophages transfected with scrambled shRNA were still able to inhibit hair reconstitution in the 
patch assay, this was rescued by OSM knock-down. Data from 3 patches per condition, across 2 independent 
experiments.Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p<0.0001, (G-I) Student’s unpaired t-test 
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In order to determine whether OSM in the macrophages were responsible for their inhibitory 
effects, we cultured murine peritoneal macrophages in the presence of M-CSF to skew them to 
a tissue-resident, anti-inflammatory phenotype [219]. shRNA was utilized to knock-down OSM 
expression (Figure 2.20H). While macrophages with scrambled shRNA were still able to inhibit 
hair reconstitution, knock-down of OSM in macrophages attenuated the inhibitory properties of 
the macrophages, and restored the original hair reconstitution of this assay (Figure 2.20I). 
These data show that OSM produced by the macrophages is the cytokine that inhibits 










Here, we uncover a new mechanism for JAK-STAT signaling in the maintenance of HFSC 
quiescence. We identify a distinct subset of TREM2+ tissue macrophages in the dermis that 
secrete OSM, which prevents proliferation of HFSC, particularly during the second telogen 
(Figure 2.21A). Our findings add to the growing literature in support of immune cells having 
direct effects on tissue stem cell regulation and control. We propose the name “trichophages” to 





Macrophages have previously been shown to have intimate interactions with HFSCs. 
Macrophages have been described to cluster around hair follicles [36], and may secrete FGF-5 
Figure 2.21. Schematic of OSM-producing macrophages during telogen. A. Tissue resident TREM2+ 
macrophages with an anti-inflammatory phenotype produce OSM during early- and mid-telogen, which signals via 
JAK-STAT5 in HFSC to maintain their quiescence. These “trichophages” predominate during early and mid telogen, 
and lose their OSM-producing ability as telogen progresses, which allows the HFs to enter the next anagen stage. B. 
Summary of experiments reported in this paper that successfully initiated anagen in telogen skin. Targeting multiple 




that promotes catagen [27, 28]. Castellana et al showed that macrophages numbers fluctuate 
during the second telogen, and peak during mid-telogen, whereby their inhibition by clodronate 
liposomes was sufficient to induce anagen [89]. We corroborate their data molecularly (with 
neutralizing antibodies), pharmacologically (with Csf1r antagonists) and genetically (with Csf1r-
CreER::iDTR mice) (Figure 2.21B). We also showed that knocking down OSM in cultured 
macrophages removes their ability to inhibit hair regeneration in a patch assay (Figure 2.21B). 
The importance of “trichophages” in the maintenance of telogen reflects the understanding that 
macrophages have a significant and integral non-immune role in many tissues, including the 
brain, where they perform essential developmental and homeostatic functions like synaptic 
pruning [220], and also the heart where they facilitate electrical conduction [90].  
 
Our single-cell RNA-sequencing data uncovered a small, yet distinct subset of macrophages 
that secrete OSM during telogen. These trichophages appear to be genetically similar to 
microglia, and might perform similar functions with respect to the hair cycle. Microglia are 
important supportive cells of the brain and CNS, where they carry out innate immune functions, 
clear cell debris, and participate in homeostasis and pruning of neurons [221]. TREM2-DAP12 
signaling in microglia have been functionally linked to their survival [222] and role in 
phagocytosis [223]. This may be analogous to the proposed role of trichophages in the hair 
cycle, where they modulate HFSC activity and coordinate the cyclical growth and regression of 
hair follicles. In the CNS, dysfunctional microglia have been implicated in the pathogenesis of 
Alzheimer’s disease, and mutations in TREM2 have been associated with neurodegenerative 
disease in humans [91, 224]. Whole exome sequencing has implicated TREM2 in diseases 
such as polycystic lipomembranous osteodysplsia (PLOSL) [225] and frontotemporal dementia 
(FTD) [226], but a distinct hair pathology has not been described in these patients. Whether 
trichophage dysfunction may lead to hair disorders associated with hair cycle abnormalities (eg. 
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Telogen effluvium, androgenetic alopecia) is an interesting avenue for future translational 
research.  
 
Macrophage heterogeneity in the skin likely reflects the constant remodeling that occurs during 
the hair cycle. This is important when considering macrophage involvement in other anagen-
inducing processes (Table S1). For example, in plucking induced anagen, damaged hair follicles 
release CCL2, which attract TNF-producing “M1-like” inflammatory macrophages that initiate 
anagen in surrounding follicles [82], a function that is opposite to the proposed role of the 
trichophage. This pathway may have evolved to maintain a coat of fur in rodents following 
environmental or predator-inflicted damage. Other fluctuations of the immune system with the 
hair cycle have been described [227, 228], and parts of it have been elucidated. For example, 
depilation-induced anagen is mediated by Jag1-Notch signaling from T regulatory cells [83, 
229], and wound-induced hair follicle neogenesis (WIHN) involves recruitment of FGF9-
secreting γδ T cells [85]. T regs do not appear to be involved in the spontaneous anagen 
initiated by JAK inhibition, or macrophage inhibition/depletion in our study, as they do in anagen 
resulting from depilation. From our observation that the TREM2+ trichophages decrease as 
telogen progresses, along with the pseudotime analysis of TREM2+ macrophage differentiation 
trajectories, it can be hypothesized that the trichophages differentiate into a M2-like, tissue-
resident phenotype over time. Whether the TREM2+ trichophages can also differentiate into 
“M1-like” macrophages in response to plucking, or whether they produce chemokines or factors 
that recruit other cell types that influence the hair cycle, are intriguing questions for future 
studies. 
 
In the mouse, administration of recombinant OSM was shown previously to be a potent inhibitor 
of anagen [137], but until now, its source and physiological contribution to the hair cycle 
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remained undefined. In humans, OSM was first discovered as a negative growth regulator of the 
A375 melanoma cell line [136], at a time when researchers were hunting for endogenous 
regulators of cancer cell growth. While OSM was first isolated in the supernatant of histiocytic 
lymphoma cells [136], it was found to be more reliably obtained from macrophage cell lines 
[199]. OSM has roles in development, inflammation and hematopoiesis [230, 231]. OSM 
appears to play a pro-inflammatory role in human keratinocytes [232, 233], causing epidermal 
hyperplasia in the context of some diseases, but also having inhibitory effects on keratinocyte 
differentiation under other conditions [138]. Lately, OSM is emerging as an important cytokine in 
tissue remodeling and regeneration in humans. OSM produced by M2-like macrophages during 
acute hepatic injury in mice was associated with a pro-fibrotic phenotype [234] . Macrophage 
OSM has also been shown to induce bone formation by mesenchymal stem cells during 
physiological osteogenesis [235], as well as in pathological Ewing sarcoma [236]. OSM has also 
been shown to be secreted in excess by mononuclear cells of patients with systemic sclerosis 
[237], and has pro-fibrotic effects in the skin and lung [238, 239]. Monoclonal antibodies against 
OSM are currently undergoing Phase I and II trials for the treatment of systemic sclerosis 
(Clinical Trial # NCT03041025). Whether there is an analogous subset of OSM-producing 
trichophages in humans that is involved in the hair cycle is an open question. 
 
Murine HFSCs of the bulge and HG express both the receptor (OSMRβ) and co-receptor 
(gp130) necessary for OSM signaling, which occurs via the JAK-STAT and MAPK signaling 
pathways. We show here that STAT5 is the most likely downstream mediator of quiescence in 
HFSC, since the activated phosphorylated form of STAT5 in the HFSC coincides with the early-
to-mid second telogen, and its genetic ablation was sufficient for initiating anagen during 
telogen. OSM signaling via the JAK-STAT5 pathway inhibits adipocyte terminal differentiation 
[210], delays cell cycle entry in HepG2 cells [211], and suppresses cytokine secretion in T cells 
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[212]. Further, the murine OSMRβ subunit is believed to directly recruit JAK2 to phosphorylate 
STAT5 in response to ligand binding [240].   
 
The maintenance of quiescence via JAK-STAT signaling is emerging as a common theme, 
where its role is evolutionary conserved. JAK-STAT signaling in the Drosophila testis is 
mediated by the ligand Unpaired, which is the fly homologue of IL-6, and signals via STAT92E 
to prevent differentiation of the germline stem cells [241]. JAK2-STAT5 signaling in murine 
hepatic stellate stem cells mediates quiescence signals from vitamin A and insulin [122]. In the 
murine mammary gland, another organ that undergoes controlled cycles of growth and 
involution, JAK-STAT3 transmits signals via LIF (another gp130-dependent cytokine) to mediate 
involution [242], while JAK-STAT5 transmits signals from Prolactin (PRL) during lactation to 
increase milk production [243]. Interestingly, during pregnancy and lactation, PRL signaling 
occurs via JAK-STAT5 in the HFSC to maintain quiescence of the hair follicles, perhaps to 
conserve nutritional resources during pregnancy [120, 147]. Here, we show that the JAK-STAT5 
pathway downstream of OSM to maintains HFSC quiescence is physiologically relevant during 
telogen in male and female mice, and may represent a novel paradigm in the control of stem 
cell quiescence.  
 
In mice, JAK-STAT3 signaling has been shown to be required for the initiation of spontaneous 
anagen, but not for plucking-induced anagen [19]. We showed that both STAT3 and STAT5 
signaling is dynamically expressed across telogen, but only pSTAT5 is specific for the HFSC 
during this phase. Further, using the covalent JAK3 inhibitor PF-06651600, we show that 
inhibition of the JAK3-STAT5 signaling axis alone in HFSCs is sufficient to initiate anagen. The 
role of STAT3 in keratinocyte differentiation and migration is distinct from the role of STAT5 in 
maintaining HFSC quiescence. STAT3 and STAT5 signaling likely contribute to complementary 
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forces of quiescence and proliferation/migration, and may interact in the coordination of the 
induced hair cycle (ie. in response to plucking, depilation and wounding). 
 
Our findings may potentially expand the indications of JAK inhibitors in the treatment of skin and 
hair diseases.  JAK inhibitors have been FDA approved for the treatment of rheumatoid arthritis 
(RA) (Tofacitinib), and myelofibrosis (Ruxolitinib). Both these drugs have been shown to be 
efficacious in the treatment of alopecia areata (AA), an autoimmune form of hair loss [244, 245], 
where their mode of action likely lies in the inhibition of pathogenic NKG2D+ CD8+ T cells. In 
our mouse models, topical JAK inhibitors induced a more robust anagen than systemic 
treatment [102, 104], in agreement with our findings that the local effect on the HFSCs is 
important for anagen initiation.  Topical formulations of JAK inhibitors are currently being 
developed for AA, and may potentially have a more potent effect on the HFSCs to stimulate 
regrowth after the autoimmune attack has been treated. The role of topical JAK inhibitors in the 
treatment of other alopecias, particularly those associated with arrested or prolonged telogen, 






CHAPTER 3. JAK-STAT SIGNALING IN THE MURINE HAIR CYCLE 
 
Our interest in JAK-STAT signaling in the hair cycle stemmed from the serendipitous 
observation that JAK inhibitors were more potent at reversing the mouse model of Alopecia 
Areata (AA) when applied topically, compared with systemic administration [102]. This led to 
further investigation into the role of JAK inhibitors in the hair cycle of normal C57BL/6 mice 
(without AA), and the conclusion that JAK inhibition stimulated anagen in a manner that 
resembled spontaneous anagen [104]. In addition to JAK-STAT5 signaling (discussed in the 
previous chapter), at the start of this project, we were also interested in examining the 
contribution of JAK-STAT3 signaling in the murine hair cycle. 
 
Unlike JAK-STAT5 signaling, the role of JAK-STAT3 signaling pathway in the skin and hair 
follicle is better documented. STAT3 is essential in embryogenesis, and is the only STAT family 
member that is embryonic lethal when knocked out globally [109]. STAT3 in the epidermis has 
been extensively studied with respect to its role in cellular functions like differentiation, 
migration, epithelial-to-mesenchymal transition, and carcinogenesis [246-248]. With respect to 
the hair cycle, Sano et al showed that constitutive STAT3 ablation in the epidermis (with a K5-
Cre driver) did not have an effect on HF morphogenesis. The major effect was on hair cycling, 
and it was shown that hair follicles (HFs) were arrested in the first telogen phase and unable to 
spontaneously enter the next anagen [115]. Interestingly, while STAT3 appeared to be required 
for spontaneous anagen entry, it was shown to be dispensable for plucking-induced anagen, 
which was postulated to occur via the PI3K-Akt signaling pathway [19]. Thus, the role for STAT3 




In this section, we examine further the role of STAT3 in the murine hair cycle, and we review 
negative data and experiments that did not succeed. The early decision to focus on the role of  
STAT5 during hair cycling allowed us to more fully interrogate its role in hair cycling, which was 




Activated pSTAT3 distribution in the HF  
 
Unlike pSTAT5, whose expression is restricted to the DP and the HFSC particularly during 
telogen (Figure 2.4B), pSTAT3 has a less well-defined distribution in the skin and HF. There is a 
constitutive activation of STAT3 on serine 727 (S727), and nuclear pSTAT3-S727 is observed in 
the epidermis, HF and DP at all stages of the hair cycle. The other phosphorylation site for 
STAT3 (tyrosine 705, Y705), which has a more restricted pattern of activation, and appears in 
the outer root sheath (ORS) at P22 and at the DP-HG junction during telogen. This expression 
becomes more prominent in the bulge and the isthmus HFSCs by the end of telogen at P80 


































































































































































































































































Ablation of STAT5 using multiple Cre-drivers induces anagen  
 
In addition to the K5-CreERT2 driver transgene discussed in the previous chapter, we also 
introduced K14-CreER, K15-CrePR and K17-CreERT2 driver transgenes into STAT5FL/FL mice. 
We successfully induced anagen with STAT5 ablation using the K14 and K17 drivers during 
mid-telogen (Figure 3.2), similar to the results with the K5-CreERT2 driver. Since K14 is 
expressed in the entire epidermis, and K17 is restricted to the HF, all three drivers are expected 
to target the HFSCs in both the bulge and HG. Surprisingly, when genetic ablation of STAT5 
was performed with the K15-CrePR driver during mid-telogen, which targets Cre recombinase 
expression to just the bulge HFSC (but not the HG), anagen was not initiated. This finding 
suggests that JAK-STAT5 mediated quiescence is most crucial in the HFSCs of the HG, rather 
than the bulge. Indeed, we have shown that STAT5 ablation results in proliferation of the HG 






Epidermal ablation of STAT5 has minimal effect on HFSC stem cell identity 
 
To determine the downstream effects of JAK-STAT5 inhibition on HFSCs, qRT-PCR was 
performed on flow-sorted bulge cells (CD34+) and HG cells (P-cad+), 10 and 20 days after 
systemic Tamoxifen induction in K5-CreERT2::STAT5a/bFL/FL mice . These time points 
correspond to those used to analyze HG proliferation in Section 2.XX. Known STAT5-response 
genes (CCDN1, CDKN1a, IRF-1, IL2ra, PIM1, Cish) and HFSC stem cell markers (NFATc1, 
Lhx2, Axin2, Tcf3, Tcf4, SOX9) were selected from the literature [43, 249-253], and their relative 
expression in the HFSC was analyzed after STAT5 ablation. 
Figure 3.2. Conditional 
ablation of STAT5 in various 
epidermal compartments. 
Using Cre-drivers expressed 
under the K5/K14 promoters 
(entire epidermis and HF), and 
the K17 promoter (just the HF), 
STAT5 ablation successfully 
initiated anagen in 
STAT5a/bFL/FL mice earlier than 
littermate controls. 
Interestingly, targeting STAT5 
ablation to the bulge with K15-
CrePR did not induce anagen. 
This suggests that the HG (a 
compartment that is in the HF, 
and not the bulge) is the likely 
responsive target of STAT5 
ablation. Results are 
representative of at least 5 
litters per Cre driver, with at 
least 1 homozygous STATFL/FL 




Ten days after tamoxifen induction (D10), there was no significant suppression of putative 
STAT5-response genes in either the bulge or HG. However, by D20, the pattern of suppression 
of these genes in the bulge and HG were strikingly different (Figure 3.3A). In the bulge, 
significant suppression of CCDN1, IL2ra and PIM1 was observed 20 days after STAT5 
conditional ablation, whereas CCDN1, CDKN1a, IRF-1 and IL2ra were suppressed in the HG. 
Although these target genes were identified in other cell types (mainly immune cells), their role 
in epithelial stem cells remains undefined. The change in their expression in bulge vs HG cells 
following STAT5 ablation suggests that downstream effectors of JAK-STAT5 signaling in the 
bulge vs HG are fundamentally different, likely due to differences in stem cell identity, chromatin 
structure, and the presence of co-factors and other transcription factors. 
 
We next investigated the stem cell markers, which tend to be associated with quiescence and 
self-renewal of the HFSCs. STAT5 ablation had little effect on bulge stem cells markers at D10, 
but significantly perturbed these genes in the HG. By D20, stem cell markers were generally 
repressed in both bulge and HG HFSCs, except for Tcf3 expression in the HG, which was 
upregulated in the HG by D10. Tcf3 is a downstream element of Wnt/β-catenin signaling, and is 
consistent with the observation that proliferation is first observed in the HG. 
 
These results were corroborated with immunofluorescence studies of telogen HFs performed 
ten days after STAT5 ablation (Figure 3.3B). The level of pSTAT5 in both bulge and HG was 
markedly decreased, but the expression of NFATc1, Lhx2, SOX9 and FoxC1 were unchanged. 
FoxC1 is a newly described quiescence factor in murine telogen HFs [48]. Increased nuclear 





Figure 3.3. Analysis of STAT5-response genes and stem cells markers in the bulge and germ (HG) of STAT5-
cKO mice. A. qRT-PCR of STAT5a/b, STAT5-respones genes, and stem cell markers in CD34+ bulge and P-cad+ 
HG at D10 and D20 days after tamoxifen induction. Expression normalized to GAPDH and WT littermates at each 
timepoint. n = 3 pairs of mice per timepoint. Data are mean ± SEM. At D20, green bars represent increased 
expression, while red bars represent decreased expression. B. IF studies of D10 telogen HFs in WT and STAT5-cKO 
mice. Note slightly increased Tcf3 expression in HG of STAT5-cKO mice (arrows). Scale bar 25µm. 
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STAT5 ablation has different effects on bulge and germ proliferation 
 
In order to determine the effects of STAT5 ablation in the different stem cell compartments of 
the skin, colony forming assays were performed on epidermal stem cells sorted by FACS. 
Interfollicular epidermal (IFE), bulge and HG stem cells from WT or K5-CreERT2::STAT5a/bFL/FL 
mice were plated and cultured for 2 weeks, with or without the addition of Tofacitinib. Tofacitinib 
had little effect on IFE stem cells, but increased the colony-forming ability of both bulge and HG 
cells (Figure 3.4). Intriguingly, STAT5-ablation had very little effect on bulge stem cells, even in 
vitro, but was associated with increased colonies of HG stem cells, to the level of Tofacitinib 
treatment. Thus, while JAK inhibition was able to enhance proliferation of bulge stem cells, it 
does not do so via STAT5. Further, in keeping with our observations in vivo, the loss of STAT5 




Figure 3.4. Colony forming assay of WT and STAT5-cKO epidermal stem cells. JAK-inhibition has minimal effects on 
IFE cells, while Tofacitinib treatment increased colony-forming abilities of bulge and HG stem cells. While STAT5-KO 
had no effect on bulge proliferation, it was associated with increased HG proliferation. IFE = Interfollicular Epidermis, 
HG = Hair Germ. Data are mean + SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p<0.0001Two-way ANOVA of 
genotype, followed by Tofacitinib treatment. 
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In silico analysis of STAT5 response elements and target genes 
 
In order to identify downstream quiescence genes that may be affected by STAT5 ablation, we 
used published datasets to identify STAT5-response genes whose expression changes in a 
pattern that correlates with that of pSTAT5 activation in HFSCs. Greco et al performed RNA-
sequencing on flow-sorted bulge, HG and DP cells from early (P43), mid (P56) and late (P69) 
telogen in wild-type C57BL/6 mice [52]. Their data showed that telogen HG cells were more 
transcriptionally active than the bulge. They also showed upregulated Wnt/β-catenin signaling at 
late telogen, which supports our findings in the previous section.  
 
Using published ChIP-seq information on STAT5a/b binding elements [249, 250, 254], we 
performed an in silico ChIP-seq to identify likely STAT5-response genes in the HG of the Greco 
dataset (GSE15185). Next, we filtered this list of STAT5-response genes to find those that had 
relative expression levels that matched the pattern of pSTAT5 activation in the epidermis (ie. 
highest during mid-telogen) (Figure 3.4, inset). When viewed on a heatmap, we observed that 
putative STAT5-response genes were more dynamically expressed in the HG across telogen, in 
agreement with findings by Greco et al. This in silico experiment suggested that JAK-STAT5 
signaling in the HFSC of the HG is dynamically regulated across telogen. The gene that best 



































































































































































































































































ID1 is a marker of quiescence downstream of JAK-STAT5 signaling 
 
ID1 (Inhibitor of DNA-binding, or Inhibitor of Differentiation) is a transcriptional repressor that 
has been identified to be downstream of BMP-SMAD1/5 signaling in the HFSC [13]. ID1 has 
also been shown to be upregulated in myoblasts in response to OSM stimulation, where it 
inhibited differentiation of myoblasts [206]. Using our in silico ChIP-seq data, we found that ID1 
expression in the HG is dynamic, and peaks during mid-telogen (Figure 3.5A). In contrast, ID1 
expression in the bulge and DP does not change throughout telogen. Using 
immunofluorescence studies, we found nuclear ID1 to be most prominent in HFSCs during early 
telogen, and its expression is reduced in the HG by late telogen. During anagen, ID1 expression 
is maintained in the bulge, but is absent from the ORS and matrix keratinocytes, consistent with 
the known role of ID1 in maintaining HFSC quiescence (Figure 3.5B). 
 
We next performed qRT-PCR on flow-sorted HG cells at D20 after tamoxifen induction of K5-
CreERT2::STAT5a/b
FL/FL mice and control littermates. We found that STAT5 ablation is 
associated with a significant downregulation of the ID1b isoform (Figure 3.5C), which has been 
shown to be a mediator of stem cell quiescence and self-renewal [255]. Using 
immunofluorescence, we showed that STAT5 ablation is also associated with loss of nuclear 
ID1 in both the bulge and HG as early at D10. This is accompanied by increased EdU 







Figure 3.6. ID1 as a quiescence factor in HFSCs. A. ID1 expression peaks 
in mid-telogen (red line) according to datasets published by Greco et al. B. IF 
studies of a HF as it progresses from telogen to anagen. Nuclear ID1 (green) 
is prominent in the telogen HFSC, and is not expressed in the proliferative 
ORS or matrix during anagen. ID1 expression is maintained in the bulge 
throughout. Dotted line circles the DP. C. STAT5 ablation is associated with 
a selective downregulation of the ID1b isoform in HG. n = 3 mice per 
genotype. Data are mean ± SEM.  D. STAT5 ablation is associated with loss 
of nuclear ID1 in both bulge and HG, and proliferation of the HG as seen by 
EdU incorporation (arrowheads). Scale bars = 25µm. 
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Initial Experiments: Attempted ablation of STAT3FL/FL mice did not induce anagen 
 
Early in the project, we asked if STAT3 had a similar role in maintaining HFSC quiescence by 
genetically ablating STAT3 during mid-telogen. Using the same K5-CreERT2, K15-CrePR and 
K17-CreERT2 drivers (last one data not shown), no early entry into anagen was observed, 
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STAT3 expression was unchanged despite tamoxifen administration 
 
During analysis of these experiments, we were puzzled that we were not able to show ablation 
of STAT3 by immunofluorescence, or by Western blot in the isolated epidermis of homozygous 
mutant mice (Figure 3.7A-B). In order to address this, we first checked the validity of out K17-
CreERT2 driver by breeding the STAT3FL/FL locus into a K17-CreERT2::R26-mTmG reporter 
strain. Tamoxifen induction of this mouse (K17-CreERT2::STAT3FL/FL::R26-mTmG) resulted in 
mGFP expression restricted to the HF (Figure 3.7C), reflecting the expected spatial and 
temporal expression of a functional Cre recombinase. To determine whether the genomic 
recombination had taken place, we used flow cytometry to isolate the GFP+ cells of the HF, and 
demonstrated, disappointingly, that STAT3 was not ablated using two different sets of primers 
(Figure 3.7D). 
 
Upstream loxP site was disrupted in the STAT3FL/FL mouse 
 
Because the Cre recombinase enzyme was functional and expressed in an expected manner as 
revealed by our reporter mouse, in order to determine the reason for the failed recombination 
event, we next asked if there was a mutation within with the floxed STAT3 allele itself. 
Sequencing primers were designed to flank Introns 17 and 20 of the STAT3 allele [256], where 
the loxP sites were inserted. While the 34bp loxP sequence was found intact in Intron 20, we 
failed to locate the other loxP site in Intron 17 (Figure 3.8). This unfortunate discovery came 
after nearly 1 year of work on the STAT3 allele, and taught us a lesson to always sequence the 







Figure 3.8. Assessment of STAT3FL/FL 
mice. A. IF studies for total STAT3 in skin 
and HF of K5-CreERT2::STAT3FL/FL mice 
and control littermates showed no 
difference expression. B. Western blot for 
total STAT3 in dissociated epidermal and 
dermal fractions of K5-
CreERT2::STAT3FL/FL mice and control 
littermates shows no significant reduction 
in STAT3 expression in mutant skin. C. IF 
studies of K17-CreERT2::R26-mTmG 
shows that the Cre-recombinase is 
functional, and expressed only in the HF, 
as expected. D. qRT-PCR of FAC-sorted 
GFP+ cells in K17-CreERT2::R26-
mTmG::STAT3FL/FL mice shows these cells 
to be expressing STAT3. Two sets of 
primers were used: STAT3 and STAT3.2. 







Second set of Experiments: Epidermal STAT3 ablation – with intact loxP sites 
 
After ordering a new STAT3FL/WT breeder pair from Jackson Laboratories, homozygous 
STAT3FL/FL were generated and genomic DNA was immediately sequenced to verify the 
presence and integrity of both loxP sites. This time, the loxP sites in both Introns 17 and 20 
were present and intact (Figure 3.9A). These mice were further bred with K5-CreERT2 mice, 
and Tamoxifen induction of STAT3 ablation in mid-telogen (P53-P60) was carried out in 2 
separate litters to date. Preliminary results (work is ongoing) show that anagen initiation does 
not occur at the time typical for K5-CreERT2::STAT5a/bFL/FL ablation (ie. around 3 weeks after 
tamoxifen administration) (Figure 3.9B). While these preliminary data support our hypothesis of 
Figure 3.9. Sequencing of loxP sites in introns 17 and 20 of STAT3 locus. STAT3FL/FL mice developed by Moh et 
al, 2007 were obtained from the Jackson Laboratories. Genotyping primers targeted intron-20, which had the intact 
loxP site. Sequencing of intron-17 showed loss of the other loxP site. 
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different roles of STAT3 and STAT5 in the hair cycle, these mice require extensive 







Figure 3.10. A. Sequencing of 
Intron 17 of new STAT3FL/FL 
mice re-ordered from Jackson 
Laboratories, with the 34-mer loxP 
site highlighted in yellow. B. 
Preliminary epidermal STAT3 
ablation during mid-telogen 
showing no effect on the telogen-
to-anagen transition, supporting 
our hypothesis of differential roles 
for STAT3 and STAT5 in the hair 






While both JAK-STAT3 and JAK-STAT5 signaling are dispensable for HF morphogenesis [19, 
115, 118, 119], they appear to have distinct roles in the adult hair cycle. Most of the other 
signaling pathways of the hair cycle are believed to have been reprised from HF morphogenesis 
[9], whereas the role of JAK-STAT signaling in the control of the hair cycle appears to be most 
physiologically relevant during adulthood.  
 
Genetic ablation of STAT5 in the various compartments of the skin and HF suggested that the 
HG is the most sensitive compartment that responds to JAK-STAT5 inhibition. This finding is in 
agreement with our previous observation that the HG is also the first to proliferate in response to 
pharmacological JAK-inhibition [104], and also in spontaneous anagen [52]. Greco et al also 
found the HG to be the most transcriptionally dynamic population during telogen [52], which may 
in part reflect active JAK-STAT5 signaling by OSM to promote quiescence. 
 
Other signals that have been postulated to maintain HFSC quiescence include BMP2/4-
SMAD1/5 signaling from the dermis and subcutaneous fat [39], FGF-18 and BMP-6 signaling 
from the K6+ inner bulge [40], and autocrine Wnt/Axin-2 signaling from the HFSC themselves 
[41]. These signals may contribute in part to defining the epigenetic state of HFSCs. BMP4 in 
particular leads to reduction of H3 K4/K9/K27me3 methylation in HFSCs, which allows stem cell 
plasticity and self-renewal [257]. Wnt signaling in the HFSC niche has also been associated with 
downstream Tcf3/Tcf4 occupancy in the HFSC-related genes, where they act to repress stem 
cell activation [258]. While the effect of JAK-STAT signaling on these complex interactions has 
not been studied in the HFSC, STAT5 has been shown to be involved in chromatin re-
organization in cultured mammary epithelial cells [259].  
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Our data suggests that STAT5 ablation in the HFSC leads to distinct changes of Tcf3/Tcf4 in the 
bulge vs HG (ie. both are repressed in the bulge at D20, but Tcf3 is upregulated >> Tcf4 in the 
HG), which is likely to affect the transcriptional status of HFSCs in significant ways. 
Interestingly, JAK-STAT3 downstream of OSM signaling in human mammary epithelial cells has 
been reported to cooperate with TGF-β/SMAD3 signaling to regulate senescence in human 
mammary epithelial cells [208]. This pathway is highjacked by breast cancer to drive epithelial-
mesenchymal transition to increase invasiveness [260]. STAT/SMAD interactions should be 
explored further in the HFSC, since we uncovered ID1 to be a possible STAT5-response gene 
in the HG, where it has previously been linked to pSMAD-1/5 signaling [13]. Thus, cross-talk 
and interactions between these various signaling pathways are likely to contribute to varying 
patterns of activation observed during the normal hair cycle [63]. 
 
JAK-STAT signaling during adulthood may allow the hair cycle to respond to environmental 
insults. The stereotypical phases of regression and regeneration during the hair cycle can be 
utilized for wound healing, hair regrowth and even de novo HF neogenesis. While JAK-STAT3 
signaling appears to be required for entry into spontaneous anagen, this pathway can be 
circumvented in the case of plucking, whereby anagen initiation can proceed in the absence of 
STAT3 [19]. This redundancy in signaling pathways allows for the regrowth of hair that has been 
plucked or removed forcibly by initiating the hair cycle, independently of JAK-STAT3 signaling. 
JAK-STAT5 signaling in the HFSC is central for maintaining quiescence, which is not a feature 
that is prominent during morphogenesis. Thus, in adulthood, JAK-STAT5 signaling by OSM 
during normal telogen, as well as by PRL during pregnancy and lactation [120], act to prevent 
premature or unnecessary HFSC activation and proliferation, in order to maintain the stem cell 




Due to a defective loxP site, our STAT3FL/FL mice experiments were unfortunately not initially 
successful. The defective loxP was uncovered after about a year of failed experiments and 
troubleshooting, and advice from many colleagues and advisors. Fortunately, although STAT3 
and STAT5 have similar dynamics across telogen, our experiments showed that ablation of 
STAT5 alone in the epidermis and HF is sufficient to induce anagen.  
 
Whether STAT5-ablation-induced anagen is a STAT3-dependent process will be an interesting 
question for future research. Future experiments on STAT3/STAT5 double-cKO mice will 
highlight the differences between spontaneous anagen and experimentally-induced anagen in 
rodents, and may reveal similar processes in humans. If anagen resulting from STAT5-ablation 
was STAT3 dependent, it may truly reflect spontaneous anagen more so than other forms of 
experimentally-induced anagen, and could be a useful new model for studying the hair cycle in 
mammals. The ability to manipulate these processes pharmacologically with increasingly 
specific small molecule inhibitors of the JAK-STAT pathway could expand the current 









In this body of work, I defined the role of JAK-STAT signaling in the maintenance of HFSC 
quiescence during telogen. This question arose from previous observations in our lab that 
application of topical JAK inhibitors was a potent inducer of anagen in mouse telogen skin. 
Using a variety of methods, I identified the JAK-STAT5 signaling pathway in HFSCs to be the 
mechanism by which quiescence is achieved. I also identified OSM as a likely upstream ligand 
that inhibits HFSC proliferation, and a distinct subset of TREM2+ macrophages that is the 
source of OSM during early-to-mid telogen. Genetic analysis of this subset of macrophages 
suggest they are ontologically similar to microglia, and may represent a class of skin-resident 





The identification of the OSM-OSMR-JAK-STAT5 axis that maintains quiescence and prevents 
HFSC proliferation in telogen provides us with a candidate “chalone” that has negative, 
inhibitory properties in the hair cycle. This discovery, along with the identification of the TREM2+ 
trichophages as the source of OSM, raises more interesting questions. 
 





My work in this thesis shows that JAK-STAT5 signaling is necessary for maintaining HFSC 
quiescence during telogen. However, evidence from the K5-Cre::STAT3FL/FL mouse studies by 
Sano et al suggest that STAT3 may play a role in anagen initiation, rather than maintaining 
HFSC quiescence. Intriguingly, while epidermal STAT3 ablation blocked entry into spontaneous 
anagen, it did not interfere with or prevent plucking-induced anagen. This finding suggests 
distinct pathways may regulate entry into spontaneous (STAT3-dependent) vs experimentally-
induced anagen (STAT3-independent) [19]. I have also recently ablated STAT3 in the epidermis 
using K5-CreERT2 with fresh STAT3FL/FL mice, and observed no effect on HFSC quiescence 
during telogen. 
 
How JAK-STAT3 and JAK-STAT5 signaling interact to control the hair cycle should be explored. 
Whether K5-CreERT2::STAT3FL/FL mice are able to initiate anagen induced by topical JAK 
inhibitors is an intriguing question, in light of STAT3-dependent and independent pathways to 
hair growth. Negative results from this experiment will strengthen the case that JAK inhibitor 
induced anagen closely resembles spontaneous anagen, and can be used as a new research 
model, in addition to plucking- and depilation-induced anagen, which induce immunological 
insults that may confound some experiments. Further, by targeting genetic ablation of STAT3 
and/or STAT5 to the skin and HF, it should be possible to assess if STAT3 loss will prevent 
anagen induced by STAT5 ablation during telogen.  
 
Determining the origin, fate and lineage of TREM2+ macrophages in the skin 
 
The identification of this rare, discrete subset of macrophages could only have been achieved 
with single-cell RNA sequencing. This small population would have been easily missed in bulk 
RNA-seq experiments, and flow sorting with traditional M1 and M2 markers would also have 
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overlooked this sub-population because of the known heterogeneity of TRMs [92]. However, 
their presence in the skin opens up many new avenues for research. 
 
For example: Do TREM2+ trichophages have other functions in the skin? Macrophages have 
been described to function at several points in the hair cycle, and are undoubtedly essential in 
skin homeostasis. Microglia-like macrophages have been postulated to be involved in the 
remodeling of Merkel cell-neurite complexes (D. Owens, personal communication), and could 
have additional roles in cyclic HF regeneration. Using a TREM2-CreER transgenic mouse to 
ablate this subset of macrophages at various points of the hair cycle, and detailed morphometric 
analysis of the HF and appendages at various timepoints would reveal the extent of their 
contribution. Further, the role of trichophages in wound healing and wound-induced HF 
neogenesis should also be studied. 
 
Interestingly, these TREM2+ trichophages share genetic ontology with microglia of the CNS, 
which are long-resident tissue resident macrophages derived from the embryonic yolk sac [98]. 
While most macrophages in the skin are believed to be derived from circulating monocytes, it 
will be intriguing to ask if there is a small, persistent yolk-sac derived population in the skin that 
give rise to trichophages, and whether the dermal tissue microenvironment plays a role in 
determining the function of this population. I generated preliminary data in which Csf1r-
CreER::R26-TdTomato pregnant dams were induced with tamoxifen at E8.5 to label yolk-sac 
derived macrophages, and found that less than 1% of the adult dermal macrophages arise from 
this population, compared with 85.9% of labelled microglia in the brain (Figure 4.1A). Some 
TREM2+ trichophages that cluster distinctly at P45 are also positive for CCR2 (Figure 4.1B), 
suggesting that they are recruited to the skin from the circulation during adulthood, and are not 
of yolk sac origin. Whether this cluster is heterogenous is an open question. Depleting the yolk 
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sac-derived population with an E8.5-labelled Csf1r-CreER::R26-iDTR mouse during early 
telogen would determine if this subpopulation is the only OSM-producing subset in the skin. 
   
 
 
Our data show a reduction of the TREM2+ trichophages during telogen. Unfortunately, single-
cell RNA sequencing and FACS are unable to determine the actual fate of these cells. To study 
the fate of these trichophages, a TREM2+ reporter mouse is required to perform lineage tracing 
of these cells. Do TREM2+ trichophages die, leave, or differentiate into other macrophage 
subsets over telogen? Do they become theTNF-producing macrophages that mediate plucking-
induced anagen [82]? The current available macrophage and microglia reporter mice are not 
well-suited for this experiment because they are not specific for this distinct TREM2+ 
subpopulation. For example, while CX3CR1GFP mice label microglia in the CNS, their expression 
Figure 4.1. Preliminary lineage tracing of skin macrophages. A. Macrophages were labeled at E8.5 by 
administering a pregnant dam with tamoxifen, and half of the litter was given another single dose of tamoxifen at P54. 
Pups were analyzed at P56. TdTomato+ cells were gated on CD45+ F4/80+ CD11b+ macrophages. Yolk sac derived 
macrophages are only labeled at E8.5, and comprise 0.79% of the dermal macrophages but 85.9% of CNS microglia. 
One dose of tamoxifen in adulthood labels around half of dermal macrophages. B. Single-cell RNA-seq data of 
dermal CD45+ immune cells. TREM2+ OSM-producing trichophages (red circle) are also partially CCR2+, suggesting 
a portion of them is recruited to the skin from the circulation. 
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The role of macrophages and OSM in human androgenetic alopecia (AGA) 
 
We obtained balding scalp from discarded surgical specimens of males with AGA, and using 
RNA-seq, compared their gene expression with non-balding occiput scalp using excess tissue 
hair transplantation procedures. Our preliminary human data using these unmatched 
balding/non-balding scalp samples from male donors suggest that balding scalp is enriched for 
macrophage markers and OSM (Figure 4.3A). Immunofluorescence studies of balding male 
AGA scalp also show increased FCGR1A+ macrophages that contain OSM (Figure 4.3B). 
Future endeavors to replicate this finding in matched samples should clarify OSM-producing 
macrophages are indeed associated with AGA. If confirmed, the concept of the miniaturized HF 
in AGA may be considered a form of arrested telogen and efforts to reawaken the HFSC in this 
condition with macrophage inhibition may be a feasible line of future investigation. 
 
Figure 4.2. CX3CR1 expression in P45 
dermal CD45+ immune cells. TREM2+ 
trichophages (red circle) will not be 
exclusively labelled with a CX3CR1GFP 
reporter, which is used to perform 





Assess the role of macrophages in the pathogenesis and maintenance of Alopecia Areata (AA) 
 
This project was inspired by a serendipitous observation made in our lab while investigating the 
efficacy of JAK inhibitors in the treatment of AA, therefore we should define role of 
macrophages and OSM in AA pathogenesis and disease progression. Using the C3H/HeJ 
mouse model of AA, and the macrophage inhibition techniques described in this thesis, the role 
of macrophages in AA can be interrogated. 
 
Due to their presence and ultrastructural features during murine catagen, Parakkal et al suggest 
that macrophages may be involved in actively resorbing remnants of the involuted HF during 
Figure 4.3. Macrophages and OSM in human AGA scalp. A. 
RNA-seq data from unmatched balding vs non-balding scalp 
showing enrichment of macrophage-related genes in green, and 
OSM in red, in the balding samples. B. Immunofluorescence 
studies of balding vs non-balding scalp showing more FCGR1A+ 
macrophages that co-localize with OSM in balding scalp. Scale 
bar = 50µm. 
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catagen. While macrophages are not professional antigen presenting cells (APCs), they may be 
actively processing HF antigens and epitopes that might be key in inducing autoimmunity in 
C3H/HeJ mice. Macrophage depletion with neutralizing antibodies or pharmacological 
(Pexidartinib) methods in the C3H-H3J model, along with analysis of macrophage and dendritic 
cell (DC) populations during AA disease development will address this pressing question. 
 
We have shown in this thesis that macrophages are required for maintaining HFSC quiescence 
in telogen. Since the NKG2D+ CD8+ effector cells in AA are believed to preferentially attack 
anagen HFs, it is compelling to ask if macrophage ablation during active AA will accelerate or 
attenuate the disease. It will be interesting to ask whether macrophages control the hair cycle 
during AA disease progression, or perhaps whether macrophages interact with the effector cells 
of AA to affect the presentation of disease. The presentation of AA in humans and mice 
(patches of alopecia that seem to spread centrifugally) suggest that a diffusible signal or a 
migratory cell may be involved in the progression of AA. This issue can be addressed by genetic 
and pharmacological macrophage inhibition, coupled with intravital imaging and lineage tracing 







In this thesis, I have established a role for the JAK-STAT signaling pathway in the complex 
network of cells and signals that control the mammalian hair cycle. I have shown that JAK-
STAT5 signaling in the HFSC during early- and mid-telogen is required for maintaining the 
quiescence of hair follicles, and disruption of this signaling by pharmacological or genetic means 
is sufficient for initiating hair growth. Further, I have identified potential downstream effectors of 
JAK-STAT5 signaling (ie. ID1) that may act in concert with other signaling pathways to maintain 
quiescence of the HFSC. 
 
Using state-of-the-art techniques like single-cell RNA sequencing, I uncovered a distinct subset 
of OSM-producing macrophages in the telogen dermis that contribute to the JAK-STAT5 
mediated quiescence in the HFSC.  
 
JAK-STAT signaling, while ubiquitous in stem cells and immune cells, may have distinct and 
complementary functions, even within the same cell type, as exemplified by JAK-STAT3 vs 
JAK-STAT5 signaling in the HFSC. Future development of JAK inhibitors with increased 
selectivity for specific JAK isoforms, and even direct specific STAT inhibitors, will refine our 
ability to target different cellular processes. This work highlights the potential of these drugs in 
modulating immune function, stem cell quiescence, and hair follicle regeneration, with relevance 







MATERIALS AND METHODS 
 
EXPERIMENTAL MODELS AND SUBJECT DETAILS 
 
Animals 
Mice were bred and maintained in the Russ Berrie Medical Sciences Pavilion Animal Facility in 
accordance with guidelines of the Institute of Comparative Medicine (ICM) and Institutional 
Animal Care and Use Committee (IACUC) of Columbia University. The Facility is specific 
pathogen-free, and all mice were socially housed under a 12 hour light/dark cycle. All mice were 
bred in the facility so as to have documented birth dates for accurate ages. All experiments 
were performed during the early- to mid-telogen phase of the hair cycle, or at the end of the 
previous anagen phase (P35 – P60), unless otherwise specified. K5-CreERT2::OSMRβFL/FL or 
K5-CreERT2::STAT5a/bFL/FL were compared with control littermates (No CreER or 
OSMRβwt/wt/STAT5a/bwt/wt), as were experiments using K14-CreER, K17-CreERT2 and K15-
CrePR drivers. Csf1r-CreER mice (originally FVB) were backcrossed at least 6-9 generations 
into a C57BL/6 background. For genetic ablation of macrophages, Csf1r-CreER::R26-iDTR 
mice were compared with control WT littermates (no CreER or no R26-iDTR). Csf1r-CreER 





De-identified human tissue was obtained under protocol number IRB-AAAE1921. Excess 
human scalp tissue from dermatological surgeries was collected in DMEM/10% FBS and 




Tamoxifen (Sigma-Aldrich) was dissolved in corn oil to a concentration of 10mg/ml, and mice 
were injected intraperitoneally (200µl) under light-protected conditions for 4 consecutive days. 
 
EdU  
5-ethnyl-2’-deoxyuridine (EdU, Life Technologies) was dissolved in sterile PBS to a 
concentration of 10mg/ml. For cellular dynamic studies, a single dose of 50µg/g was injected 




Hair Cycle Manipulation 
Mice were carefully shaved with clippers during telogen to reveal the pink skin typical of the 
telogen phase 1 week prior to the experiment. Mice that were inadvertently wounded were not 
used. Anagen was induced by topical application of 2% Ruxolitinib in DMSO to the right side of 
the dorsal skin daily for 5 consecutive days. The hair cycle was observed and documented with 
standardized photographs taken prior to the first treatment, and then twice weekly thereafter.  
Murine IL-6, LIF or OSM (100ng/ml, 50ng/ml, 125ng/ml respectively) were dissolved in sterile 
PBS and 100µl was injected into the center of the field of application daily for 10 consecutive 
days, beginning with the first application of Ruxolitinib.  
 
Neutralizing Antibodies 
Neutralizing antibodies to OSMR (7.5µg) were injected intradermally into the dorsal telogen skin 
daily for 14 days from P60 (mid-telogen). Neutralizing antibodies to Csf1r (AFS98) and F4/80 
(CI:A3-1) were diluted in sterile PBS, and 500µg was injected intradermally into the dorsal 
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telogen skin for 14 consecutive days. Neutralizing antibodies to CD25 (PC61.5) were injected 
intraperitoneally every other day (250µg/dose x 3) from P53, prior to anagen induction at P60. 
 
Flow Cytometry 
Dorsal skin was processed for either epidermal or dermal single-cell suspensions for stem cell 
or immune cell analysis by flow cytometry. Full thickness skin was harvested and defatted, and 
floated on 0.25% Trypsin for 30 min at 37°C. Epidermal cells were scraped off and titurated in 
DMEM/10%FBS before filtering through a 70µm mesh and centrifuged to obtain the epidermal 
cell pellet. The dermis was macerated finely with dissection scissors and re-suspended in 5ml 
DMEM with 0.2% Collagenase IV and 300U DNase 1, and incubated in a 37°C water bath for 40 
minutes. The digested dermis was titurated in DMEM/10%FBS and filtered through a 70µm 
mesh and centrifuged. Mouse brain tissue was physically macerated with glass slides, and 
digested with 0.2% Collagenase IV and DNase, filtered, and microglia were isolated with a 30%-
37%-70% Percoll gradient. Cells were labelled with conjugated surface antibodies listed in the 
Key Resources Table in DMEM/2%FBS for 1h on ice, and washed and labelled with live/dead 
Hoescht stain prior to FACS. Flow cytometry was performed on the Influx sorter in the Columbia 
University Flow Cytometry Core. Epidermal cell suspensions were used for HFSC stem cell 
analysis, and dermal suspensions were sorted for dermal papilla and immune cell experiments.  
Cells were collected in DMEM/10%FBS for cell culture, or in Trizol for RNA extraction. Flow 
cytometry data was analyzed using FlowJo software (FlowJo, LLC). 
 
Cell Culture  
HFSCs (ITGA6+ Sca-1-) cells were collected from flow cytometry and plated onto 6-well plates, 
and maintained with Cnt-07S keratinocyte media. In vitro stimulation experiments were carried 
out when keratinocytes were 80-90% confluent. Confluent HFSCs were pre-treated with JAK 
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inhibitors (tofacitinib, ruxolitinib or PF-06651600, all at 10µM) for 20 min, and murine OSM was 
added for a final concentration of 10ng/ml or 20ng/ml for 15 min. For clonogenic assays, HFSCs 
were plated at a density of 10,000 cells per well and maintained for 2 weeks. For analysis of 
clonogenicity, plates were washed with PBS, and keratinocytes were fixed in situ with 4% 
paraformaldehyde (PFA) for 1 hour, followed by staining with 1% (wt/vol) Rhodamine B (Sigma-
Aldrich) for 1h. Clones were quantified using a backlight.  
 
qRT-PCR 
Sorted cell populations, epidermal sheets or dermal tissue was collected in Trizol and flash-
frozen overnight at -80°C. RNA was extracted with the QIAgen RNeasy Micro Kit and cDNA was 
made using Superscript IV with a 2:1 mixture of random hexamers and oligo-dT primers. Semi-
quantitative PCR for genes listed in the Key Resources Table was performed using SYBR 
Green PCR mix on an Applied Biosystems 7300 Real-Time PCR System. Primers for GAPDH 
were used in each reaction as a housekeeping control, and fold changes were calculated using 
the δ-δ Ct algorithm.  
 
Genomic Sequencing 
For sequencing of loxP sites, primers were designed manually around target introns. Genomic 
DNA was extracted from tails or ears snipped from weaned pups and PCR was performed with 
Platinum PCR Supermix (Thermo Fisher Scientific). PCR product was gel purified with QIAquick 
Gel Extraction Kit and sent for sequencing with forward primers at Genewiz 
(https://clims3.genewiz.com/). Reported .SEQ files were analyzed with Serial Cloner against 





Cells were lyzed in RIPA buffer in the presence of protease and phosphatase inhibitors on ice, 
and protein lysates were resuspended in Laemmli sample buffer. Whole-cell lysates were 
fractionated on TGX Stain-free protein gels and transferred to a PVDF membrane, blocked with 
5% non-fat milk in TBST, and incubated with antibodies listed in the Key Resources Table (all 
1:1000, diluted in TBST/3%BSA) overnight. Membranes were washed the following day and 
incubated with HRP-conjugated secondary antibodies (1:5000), washed, and developed with 
Luminata Forte Western HRP Substrate and visualized on the BioRAD ChemiDOC MP Imaging 
system. GAPDH or β-actin were used as loading controls, depending on the mass of the 
proteins of interest. 
 
Immunofluorescence and Histology 
For immunofluorescence (IF) studies, dorsal skin or human scalp biopsies were submerged in 
4% PFA for 1 hour, washed in PBS, and allowed to sink in 30% sucrose overnight before being 
embedded and frozen in OCT over liquid nitrogen. Samples were sectioned at 8µm thickness 
onto SuperFrost Plus glass slides (Fisher Scientific), blocked with 2% fish skin gelatin in 
PBS/0.3%Triton-X, and labelled with primary antibodies listed in Key Resources Table overnight 
at 4°C. Primary antibodies were washed off the following day, and labelled with fluorescence-
conjugated secondary antibodies (1:1000), and images were acquired on a Zeiss LSM 5 Exciter 
Confocal microscope. EdU labelling was carried out with Click-iT Plus Alexa Fluor 647nm 
Imaging Kit according to manufacturer’s protocol. For histology, formalin-fixed paraffin-
embedded (FFPE) sections of mouse dorsal skin were rehydrated in increasingly dilute ethanol, 







Hairpin sequences containing scramble or OSM 21mers obtained from the TRC RNAi 
consortium were cloned into the pLKO.1 library vector between the AgeI and EcoRI restriction 
sites. Modified pLKO.1 vector, along with helper packaging plasmids pMD2.G and pCMVδR8.2, 
were transfected into 293FT cells in the presence of Lipofectamine 3000 reagent, used 
according to manufacturer’s protocol. Supernatant containing lentivirus was harvested 48 hours 
after transfection, filtered through a 0.45µm syringe filter, concentrated with PEG-it viral 
precipitant, resuspended in sterile PBS, and stored at -80°C until required. 
 
Macrophage Inhibition 
For in vivo macrophage inhibition, the small molecule Pexidartinib/PLX3397 was administered 
topically (2mM in DMSO) or subcutaneously (1mM in corn oil) for 5 consecutive days from P60. 
For OSM knock-down, peritoneal macrophages were harvested from adult C57BL/6 mice and 
cultured in DMEM/F12/15%FBS/0.3mMCa2+ the presence of 0.1mg/ml M-CSF to polarize them 
to an “M2-like” phenotype. Lentiviral precipitate containing scrambled or OSM shRNA added to 
the media in the presence of 8µg/ml protamine sulphate, and the cells were centrifuged at 
3000rpm for 1h at 32°C to enhance transduction. Successful transductions were enriched with 
puromycin (1µg/ml) selection, counted and used for the patch assay. 
 
Hair Reconstitution Assays 
Neonatal (P0 or P1) mice were sacrificed and skins were harvested for the patch assay. 
Neonatal skins were enzymatically separated with 0.25% trypsin, and the dermis was further 
digested with 0.3% collagenase/DNase. Neonatal keratinocytes and dermal cells were counted 
recombined in a 1:1 ratio (106 cells each) and resuspended in 100µl of media (1:1 mix of 
DMEM/10%FBS and CnT-0.7S) and injected intradermally into the dorsal skin of a nude mouse. 
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For pharmacological/cytokine treatment, tofacitinib (400nM) and/or OSM (25ng/ml) was added. 
For macrophage inhibition assays, 20 x 103 macrophages (either freshly sorted by FACS, or 
cultured) were added to the cell slurry before injection into the Foxn1nu-2J nude mouse. 
 
Single-cell RNA Sequencing 
Live CD45+ immune cells from the dermis was isolated by FACS at early, mid and late telogen, 
captured on a microfluidic chip, and processed for single-cell RNA sequencing with the 10X 
Genomics Chromium 3’ Solution platform. cDNA synthesized by this method was amplified and 
sequenced on an Illumina NextSeq. Cells with <500 or >2000 genes were excluded from 
analysis, as were cells with >105 UMIs (reflecting doublets) or mitochondrial genes >0.8% 
(reflecting dying cells). 1186 highly variable genes were identified based on their average 
expression and variance, and used for clustering analysis. Principle component analysis (PCA) 
on variable genes was performed by JackStraw analysis to identify significant PCs (p<0.05), 
and t-Distributed Stochastic Neighbor Embedding (t-SNE) plots were made based on the first 28 
PCs for all immune cells at all timepoints, and 10 PCs for just the macrophages at P45. Further 
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APPENDIX A. KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Anti-Mouse OSMRβ R&D Systems Cat# MAB662 
Anti-Mouse pSTAT1 (Y701) 
(58D6) 
Cell Signaling Cat# 9167 
Anti-Mouse pSTAT3 (Y705) 
(D3A7) 
Cell Signaling Cat# 9145 
Anti-Mouse pSTAT3 (S727) Abcam Cat# ab86430 
Anti-Mouse pSTAT5 (Y694) 
(C11C5) 
Cell Signaling Cat# 9359 
Anti-Mouse pMEK-1/2 
(Ser217/221) (41G9) 
Cell Signaling Cat# 9154 
Anti-Mouse pERK-1/2 
(Thr202/Tyr204) (197G2) 
Cell Signaling Cat# 4377 
Anti-Mouse pAkt (Thr308) 
(C31E5E) 
Cell Signaling Cat# 2965 
Anti-Mouse mTOR (7C10) Cell Signaling Cat# 2983 
Anti-Mouse β-actin-HRP Santa Cruz Cat# sc-47778 
Anti-Mouse GAPDH (6C5) Santa Cruz Cat# sc-32233 
Anti-Mouse ITGA6 FITC Serotec Cat# MCA699F 
Anti-Mouse CD34 A700 eBioscience Cat# 56-0341-82 
Anti-Mouse Sca-1 APC eBioscience Cat# 17-5981-81 
Anti-Mouse P-cadherin PE R&D Systems Cat# FAB761P 
Anti-Mouse P-cadherin R&D Systems Cat# AF761 
Anti-Mouse gp130 Neuromics Cat# MO15024 
Anti-Mouse/Human Keratin 15 Covance Cat# PCK-153P-100 
Anti-Mouse CD34 eBioscience Cat# 14-0341-82 
Anti-Mouse CD45 FITC Biolegend Cat# 103108 
Anti-Mouse Integrin-α9 PE R&D Systems Cat# FAB3827P 
Anti-Mouse F4/80 PE-Cy7 BioLegend Cat# 123114 
Anti-Mouse CD11b APC BD Pharmingen Cat# 557686 
Anti-Mouse CD11b PE eBioscience Cat# 12-0112-81 
Anti-Mouse CD163 FITC BioRAD Cat# MCA342F 
Anti-Mouse CD206 APC eBioscience Cat# 17-2061-82 
Anti-Mouse I-A/I-E APC Biolegend Cat# 107617 
Anti-Mouse OSM Abcam Cat# ab133748 
Anti-Mouse CD11b Abcam Cat# ab8878 
Anti-Mouse Aif-1/Iba-1 R&D Systems Cat# AF761 
Anti-Mouse F4/80 Life Technologies Cat# 14-4801-82 
Anti-Mouse Trem2 Abcam Cat# ab95470 
Anti-Mouse Trem2-APC R&D Systems Cat# FAB17291A 
InVivoMAb Anti-Mouse Csf1R 
(CD115) 
BioXCell Cat# AFS98 
InVivoMAb Anti-mouse F4/80 
(CI:A3-1) 
BioXCell Cat# BE0206 
InVivoPlus Anti-mouse CD25 (IL-
2Rα) (PC-61.5.3) 
BioXCell Cat# BP0012 
121 
InVivoPlus Mouse IgG2 isotype 
control 
BioXCell Cat# BP0086 
Anti-Human FCGR1A Abcam Cat# ab104273 
Anti-Human Oncostatin M (G-1) Santa Cruz Cat# sc-390253 
Anti-Mouse/Human Keratin 14 BioLegend Cat# PRB-155P 
Bacterial and Virus Strains 
pLKO.1 - TRC cloning vector Addgene Cat# 10878 
pMD2.G – packaging plasmid Addgene Cat# 12259 
pCMV delta R8.2 – packaging 
plasmid 
Addgene Cat# 12263 
Chemicals, Peptides, and Recombinant Proteins 
DMSO Sigma-Aldrich Cat# D2650-100ML 
Ruxolitinib APExBIO Cat# INCB018424 
Tofacinitb Abmole Bioscience Cat# CP-690550 
Recombinant Murine Oncostatin 
M (OSM) 
R&D Systems Cat# 495-MO-025 
Trypsin 2.5% Fisher Scientific Cat# 15090046 
Collagenase IV from Clostridium 
histolyticum 
Sigma-Aldrich Cat# C5138 
DNase I Sigma-Aldrich Cat# D5025 
CnT-07S Keratinocyte media CELLnTEC Cat# CnT-07 
Diphtheria Toxin from 
Corynebacterium diphtheriae 
Sigma-Aldrich Cat# D0564 
Tamoxifen Sigma-Aldrich Cat# T5648-1G 
EdU (5-ethynyl-2’-deoxyuridine) Life Technologies Cat# A10044 
Hoescht 33342 trihydrochloride, 
trihydrate 
Invitrogen Cat# H3570 
Pexidartinib Selleckchem Cat# S7818 
Recombinant Murine M-CSF Peprotech Cat# 315-02 
Lipofectamine 3000 Transfection 
Reagent  
Thermo Fisher Cat# L3000008 
PEG-it viral precipitant System Biosciences Cat# LV810A-1 
Critical Commercial Assays 
Click-iT™ Plus EdU Alexa 
Fluor™ 647 Imaging Kit 
ThermoFisher Cat# C10640 
RNeasy Micro Kit QIAgen Cat# 74004 
RNAscope® Advanced Cell Diagnostics Cat# 320850 
Deposited Data 
GSE15185 Greco et al, Cell Stem Cell 2009 Feb 
6;4(2):155-69 
Experimental Models: Organisms/Strains 
Mouse: C57BL/6J The Jackson Laboratory JAX: 000664 
Mouse: B6N.129S6(Cg)-
Krt5tm1.1(cre/ERT2)Blh/J 
The Jackson Laboratory JAX: 029155 
Mouse: B6;129-Osmrtm1.1Nat/J The Jackson Laboratory JAX: 011081 
Mouse: B6.129S6-Stat5btm1Mam 
Stat5atm2Mam/Mmjax 




The Jackson Laboratory JAX: 019098 
Mouse: C57BL/6-
Gt(ROSA)26Sortm1(HBEGF)Awai/J 
The Jackson Laboratory JAX: 007900 
Mouse: C57BL/6-Tg(Foxp3-
DTR/EGFP)23.2Spar/Mmjax 
The Jackson Laboratory JAX: 32050-JAX 
Mouse: B6(SJL)-Foxn1nu-
2J/GrsrJ 
The Jackson Laboratory JAX: 016195 
Oligonucleotides 
Osmr F TCT GGG TGG AGA ATT ATA GC N/A 
Osmr R CCA GGA ACT CCA GTT GCC CC N/A 
Osm F ATG CAG ACA CGG CTT CTA AGA N/A 
Osm R TTG GAG CAG CCA CGA TTG G N/A 
STAT5a F CGC CAG ATG CAA GTG TTG TAT N/A 
STAT5a R TCC TGG GGA TTA TCC AAG TCA AT N/A 
STAT5b F CAC AGT GGA TCG AAA GCC AAG N/A 
STAT5b R AGC TGG GTG GCC TTA ATG TTC N/A 
Keratin 17 F ACC ATC CGC CAG TTT ACC TC N/A 
Keratin 17 R CTA CCC AGG CCA CTA GCT GA N/A 
Il6st (gp130) F GGT CAA CTT TTG GAA CCG TG N/A 
Il6st (gp130) R GCA GCA TGG TTG GTC TTC C N/A 
Osm shRNA F CGGCACAATATCCTCGGCATA N/A 
Osm shRNA R TATGCCGAGGATATTGTGCCG N/A 
GAPDH F TGG CCT TCC GTG TTC CTA C N/A 
GAPDH R GAG TTG CTG TTG AAG TCG CA N/A 
STAT3 F GCC AAG GAG ACA TGC AGG N/A 
STAT3 R CGC CAG CTC ACT CAC AAT GC N/A 
STAT3.2 F GCT GGC TGA GAA GCT CCT AGG N/A 
STAT3.2 R CAG ACC CAG AAG GAG AAG C N/A 
STAT3 – Intron 17 sequencing F GCT GGC TGA GAA GCT CCT AGG N/A 
STAT3 – Intron 17 sequencing R TGA GTA GTT CAC ACC AGG CC N/A 
STAT3 – Intron 20 sequencing F GGT GGA AAA GGA CAT CAG TGG N/A 
STAT3 – Intron 20 sequencing R GGT GTA TGG CTC TAC AGA CTG G N/A 
Software and Algorithms 
Graphpad Prism Graphpad Software, Inc http://www.graphpad.com/ 
FlowJo FlowJo, LLC https://www.flowjo.com/solutions/flowjo 
ImageJ MIH Version https://imagej.nih.gov/ij/download.html 
Loupe Cell Browser 10X Genomics https://support.10xgenomics.com/single
-cell-gene-
expression/software/downloads/latest 
Seurat R Package http://satijalab.org/seurat/ 
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APPENDIX B. List of Abbreviations 
AA Alopecia Areata 
ACTH Adrenocorticotrophic Hormone 
AGA Androgenetic Alopecia 
Aif-1 Allograft Inflammatory Factor 1 
APC Antigen Presenting Cell 
BDNF Brain-Derived Neurotrophic Factor 
BMP Bone Morphogenetic Protein 
CCDN1 Cyclin-D1 
CCL2 C-C Chemokine Ligand 2 
CCR2 C-C Chemokine Receptor Type 2 
CDKN1a Cyclin Dependent Kinase Inhibitor 1A 
CX3CR1 CX3C Chemokine Receptor Type 3 
CD- Cluster of Differentiation- 
CFA Colony Forming Assay 
ChIP Chromatin Immunoprecipitation 
Cish Cytokine Inducible SH2 Containing Protein 
cKO Conditional Knock-Out 
CNS Central Nervous System 
Cre Causes REcombination 
CreER Cre-recombinase Estrogen Receptor 
CrePR Cre-recombinase Progesterone Receptor 
CNTF Ciliary Neurotrophic Factor 
CSF1 Colony Stimulating Factor-1 (aka M-CSF) 
124 
Csf1r Colony Stimulating Facotr-1 receptor 
CT-1 Cardiotrophin-1 
DC Dendritic Cell 
DF Dermal Fibroblasts 
DP Dermal Papilla 
DTA Diphtheria Toxin A 
EdU 5-ethynyl-2'-deoxyuridine 
ESC Embryonic Stem Cells 
GFP Green Fluorescent Protein 
GH Growth Hormone 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
FACS Fluorescence-activated cell sorting 
FGF Fibroblast Growth Factor 
FoxC1 Forkhead Box C1 
HF Hair Follicle  
HFSC Hair Follicle Stem Cell 
HG Hair Germ 
ID1 Inhibitor of DNA binding-1, or Inhibitor of Differentiation 
iDTR Inducible Diphtheria Toxin Receptor 
IGF-1 Insulin-like Growth Factor-1 
IFE Interfollicular Epidermis 
IFN Interferon 
IL- Interleukin- 
Il6st Interleukin-6 signal transducer (gene name for gp130) 
IRF-1 Interferon regulatory factor 1 
125 
IRS Inner Root Sheath 
JAK Janus Kinase 
K- Keratin- 
Lgr5 Leucine-rich repeat-containing G-protein coupled receptor 5 
Lhx2 Lim-homeobox 2 
LIF Leukemia Inhibitory Factor 
LIFRβ Leukemia Inhibitory Factor Receptor 
loxP Locus of X-over P1 
Mc Melanocyte 
M-CSF Macrophage Colony Stimulating Factor (aka CSF1) 
MEF Mouse Embryonic Fibroblasts 
MHC Major Histocompatibility Complex 
MRC1 Mannose Receptor C-Type 1 (CD206) 
mTmG Membrane-Tomato/membrane-GFP 
Mx Matrix 
NFATc1 Nuclear Factor Of Activated T-Cells 1 
NKG2D Natural-killer group 2, Member D 
ORS Outer Root Sheath 
OSM Oncostatin M 
OSMRβ Oncostatin M receptor 
P-cad P-cadherin 
PDGF-α Platelet-derived growth factor-α 
PIM1 Proviral Integration Site 1 
PRL Prolactin 
PTHrp Parathyroid hormone-related protein 
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qRT-PCR Quantitative Reverse Transcription Polymerase Chain Reaction 
R26- Rosa 26 
RNA Ribonucleic Acid 
SCC Squamous Cell Carcinoma 
scRNA-seq Single-cell RNA sequencing 
Shh Sonic Hedgehog 
SMAD Small body size + Mothers Against Decapentaplegic (portmanteau) 
SP Substance P 
SOX9 Sex determining region-box 9 
STAT Signal Transducers and Activators of Transcription 
TAC Transit Amplifying Cells 
Tcf3 Transcription Factor 3 
Tcf4 Transcription Factor 4 
TdT Tandem dimeric-Tomato 
TE Telogen Efluvium 
TGFβ Transforming Growth Factor-β 
TNF Tumor Necrosis Factor 
T reg Regulatory T Cell 
TREM2 Triggering Receptor Expressed on Myeloid Cells 2 
TRM Tissue Resident Macrophage 
WB Western Blot 
WIHN Wound-induced HF neogenesis 
Wnt Wingless-related integration 
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